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ABSTRACT 
 
HILARY CLEGG: Identification and Characterization of Two Potential Novel 
Regulators of Apoptosis, MAGE-D2 and SUMI-1 
(Under the direction of Yanping Zhang, Ph.D.) 
 
 Apoptosis is a genetically-programmed form of cell death that is critical for 
proper development, tissue homeostasis, and immune function in vertebrate 
organisms. Disrupted regulation of this process contributes to diverse diseases 
such as cancer, neurodegenerative disorders, and autoimmune dysfunction. Our 
knowledge of apoptosis is incomplete, especially the mechanisms governing 
MOMP (mitochondrial outer membrane permeabilization)—a critical control point 
during which cytochrome c and other mitochondrial intermembrane space 
proteins are released, triggering the execution of apoptosis. Our understanding of 
this process can be enhanced by identifying proteins involved in its regulation. In 
this work, two proteins—MAGE-D2 (melanoma antigen family D2) and SUMI-1 
(survival-promoting mitochondrial protein 1, also known as CHCHD2 for coiled-
coil-helix-coiled-coil-helix-domain containing 2)—are identified as novel potential 
regulators of apoptosis. Initially, these proteins were identified in a screen for 
novel interacting partners of the pro-apoptotic protein p32/C1QBP (complement 
component 1, q subcomponent binding protein). This screen was undertaken in 
an effort to better understand the mechanisms by which p32 regulates apoptosis; 
however, in this work, the functions of MAGE-D2 and SUMI-1 are characterized 
iv 
separately from p32. Here, we show that MAGE-D2 is localized to the nucleolus, 
nucleus, and possibly the mitochondria, and preliminary data suggest potential 
roles for MAGE-D2 in apoptosis and cell cycle control. SUMI-1 is characterized 
more extensively in this work, and the data presented here establish SUMI-1 as a 
novel mitochondria-localized regulator of mitochondrial fission-fusion dynamics 
and BAX-mediated apoptosis. The data shown here support a model in which 
SUMI-1 resides at the mitochondrial outer membrane, where it regulates 
mitochondrial fusion and protects cells from apoptosis. Upon treatment with 
apoptosis-inducing stimuli, SUMI-1 translocates from the mitochondria, inhibiting 
mitochondrial fusion while fission continues unperturbed. This imbalance results 
in mitochondrial fragmentation, promoting BAX oligomerization on the 
mitochondrial outer membrane and ultimately leading to MOMP, cytochrome c 
release, and apoptosis. This body of work provides a subcellular localization and 
functional data for two previously uncharacterized proteins and contributes to our 
understanding of the signaling pathways regulating apoptosis. These data, as 
well as discussion of the results and future directions, are described herein. 
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CHAPTER I 
 
INTRODUCTION 
 
An Overview of Apoptosis 
 Apoptosis is a tightly-regulated form of programmed cell death that is 
critical for proper embryonic development, tissue homeostasis, and immune 
response, and aberrant regulation of apoptosis contributes to diseases such as 
autoimmune disorders, neurodegenerative disease, and cancer. Unlike necrosis, 
or “accidental” cell death, which is usually triggered by acute cellular injury, 
apoptosis is genetically programmed and is characterized by distinct 
morphological changes such as membrane blebbing, chromatin condensation, 
DNA fragmentation, and cell shrinkage (Kerr et al., 1972). In vertebrates, 
apoptosis usually occurs through one of two major pathways: extrinsic, or 
receptor-mediated apoptosis, and intrinsic, or mitochondria-mediated apoptosis. 
Both pathways result in the activation of executioner cysteine proteases 
(Caspases), which cleave downstream targets to carry out the execution phase 
of apoptosis.  
 Apoptotic cell death was first described in 1842 by German scientist Carl 
Vogt (Vogt, 1842), but the process was not described in detail until 1972 when 
Kerr, Wyllie and Currie published a paper describing the phenomenon and 
assigning the term “apoptosis” based on a suggestion from a professor of Greek 
language, James Cormack. Apoptosis (Greek: apo – from/off/without, ptosis – 
3 
falling) translates to the "dropping off" of petals or leaves from plants or trees 
(Kerr et al., 1972). The pronunciation of this word is still debated; Kerr et al. 
suggested that the second “p” be silent to reflect the word’s Greek roots, while 
others have pointed out that, while the “p” is often silent in Greek-derived words 
that begin with a “pt” combination, a “pt” found in the middle of a word is typically 
pronounced, as in “helicopter” and “cryptic.” 
 For many multicellular organisms, apoptosis is essential during embryonic 
development. In vertebrates, many tissue and organ systems produce an 
overabundance of cells, and those cells that are not utilized must be destroyed in 
a way that does not induce an inflammatory response and is not otherwise 
detrimental to the organism. In this manner, apoptosis eliminates neurons that 
fail to establish connections (Nijhawan et al., 2000) and immune cells that fail to 
produce antigen specificity (Opferman and Korsmeyer, 2003). In adult 
organisms, apoptosis is essential for maintaining tissue homeostasis. It is 
estimated that 50-70 billion cells are produced in the human body die each day to 
replace those that are eliminated by apoptosis (Chen and Lai, 2009). During 
wound healing, apoptosis removes inflammatory cells that might otherwise lead 
to scarring or fibrosis (Greenhalgh, 1998). Apoptosis is also critical for proper 
immune response, targeting cells infected with viruses or other pathogens to 
prevent their proliferation (Roulston et al., 1999).  
Apoptosis in Disease 
 Defective regulation of apoptosis contributes to a number of human 
diseases including cancer, neurodegenerative disorders, and autoimmune 
4 
disorders. More than ten years ago, evasion of apoptosis was introduced as one 
of the six hallmarks of cancer that enable or promote tumor growth (Evan and 
Littlewood, 1998; Hanahan and Weinberg, 2000). The human body uses 
apoptosis as a defense against extensive DNA damage that may otherwise 
promote carcinogenesis; in other words, if a cell’s genetic material is sufficiently 
damaged, apoptosis is triggered in order to prevent the cell from progressing into 
a tumor (Kerr et al., 1994). Cells that escape this defense mechanism can 
potentially undergo additional changes and become transformed. Cancer cells 
employ a variety of strategies to disable induction of apoptosis. Most notable is 
inactivation of the tumor suppressor p53, which normally responds to DNA 
damage, abnormal proliferative signals, and other cellular stresses by triggering 
apoptosis, primarily through transactivation of apoptosis-promoting targets such 
as PUMA and BAX (Levine, 1997). Many chemotherapeutic agents, such as 
cisplatin, doxorubicin, and paclitaxel, fight tumors through induction of apoptosis, 
and identification of novel apoptosis-inducers and apoptosis-sensitizing agents is 
an area of ongoing investigation in cancer biology. 
  Defective apoptosis or impaired clearance of apoptotic cells can also 
contribute to immune dysfunction and development of autoimmune disorders 
such as systemic lupus erythematosus (SLE) (Stuart and Hughes, 2002). During 
T-cell development, T-cells with self-recognizing antigens are normally destroyed 
by apoptosis. If these T-cells evade apoptosis and continue to proliferate, 
autoimmune disorders can result. Type I (juvenile-onset) diabetes mellitus is 
thought to arise from T-cells that recognize and attack insulin-producing beta-
5 
cells in the pancreas. Similarly, inappropriate T-cell targeting of joints is 
presumed to occur in rheumatoid arthritis (Hayashi and Faustman, 2003), and 
the impaired apoptosis of these T-cells may result from induction of apoptosis-
inhibiting BCL-2 and MCL-1 proteins (Liu and Pope, 2003). In systemic lupus 
erythematosus, reduced apoptosis leads to lymphoproliferation and general 
autoimmunity (Hayashi and Faustman, 2003).  
 On the other hand, an excess of apoptosis can contribute to development 
of neurodegenerative disorders, the most prevalent of which is Alzheimer’s 
Disease, affecting more than 25 million people worldwide and predicted to affect 
one out of every 85 individuals by the year 2050 (Brookmeyer et al., 2007). 
Alzheimer’s Disease causes progressive neurological decline involving extensive 
neuronal loss through mechanisms that are not entirely clear but are known to 
involve accumulation of neurofibrillary tangles and β-Amyloid plaques in the 
extracellular space between neurons (Masters et al., 1985; Selkoe, 2001; 
Yankner, 1996). β-Amyloid aggregates have been shown to induce neuronal cell 
death in vivo and in cell culture (Estus et al., 1997; Hartman et al., 2005; Pike et 
al., 1991) and are thought to induce aberrant apoptosis in part through 
generation of oxidative stress and by inducing expression of Fas ligand (Ethell 
and Buhler, 2003).  In addition, the pro-apoptotic BH3-only protein BIM is 
elevated in Alzheimer’s disease, and it was shown that BIM is required for β-
Amyloid-induced neuronal cell death. β-Amyloid was shown to elevate BIM levels 
by regulating cyclin-dependent kinase 4 (CDK4) and its downstream effector B-
Myb in neuronal cell culture (Biswas et al., 2007). However, the exact 
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mechanisms that induce neuronal apoptosis in Alzheimer’s Disease are still 
unclear.  
 Parkinson’s Disease is another progressive cognitive disorder involving 
neuronal death and is the second most common neurodegenerative disease, 
affecting six million people worldwide (Dauer and Przedborski, 2003). In this 
disorder, neuronal death occurs in dopamine-producing cells in the substantia 
nigra located in the midbrain (Levy et al., 2009). Apoptosis has been postulated 
as a mechanism for the neuronal death in Parkinson’s Disease, but controversy 
surrounds the issue because one marker of apoptosis—nuclear DNA cleavage—
is not robustly present in brains of Parkinson’s Disease patients. However, a 
number of apoptotic signaling pathways have been implicated in the disorder, 
including involvement of BCL-2 family proteins, mitochondrial dysfunction, JNK 
(Jun Kinase) signaling, and activation of p53; furthermore, an apoptotic pathway 
involving BAX activation, cytochrome c release, and  activation of Caspase-9 and 
Caspase-3 has been implicated in the development of the disease (Levy et al., 
2009; Tatton et al., 2003). Understanding whether apoptosis regulates 
Parkinson’s Disease, and through what specific mechanisms and signaling 
pathways, will be essential for developing targeted therapies for this disorder. 
  
Signaling Pathways and Regulatory Mechanisms in Apoptosis 
Both the intrinsic (mitochondria-mediated) and extrinsic (receptor-
mediated) pathways converge upon a common execution pathway initiated by 
activation of executioner Caspases—Caspases-3, -7, and -9—which cleave 
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downstream targets to induce the biochemical, biophysical, and morphological 
changes that constitute apoptosis (Slee et al., 2001). Caspase-3 activates the 
endonuclease CAD by cleaving its inhibitor, ICAD, leading to chromatin 
condensation and degradation of chromosomal DNA (Sakahira et al., 1998).  The 
DNA repair enzyme poly (ADP-ribose) polymerase (PARP) is cleaved and 
inactivated in order to prevent ATP depletion (Simbulan-Rosenthal et al., 1998). 
The actin-binding protein Gelsolin is cleaved, and the resulting fragments 
subsequently cleave actin polymers, disrupting the cytoskeleton (Kothakota et 
al., 1997). The cell disintegrates into smaller, membrane-enclosed fragments 
called apoptotic bodies. In vivo, the final step of apoptosis occurs when 
phagocytic cells uptake these apoptotic bodies and recycle their contents. Cells 
undergoing apoptosis are recognized by phagocytes when phospholipids of the 
plasma membrane change orientation. Phosphatidylserine, for example, flips 
from the inner to the outer leaflet, providing a signal for disposal by 
noninflammatory phagocytes (Fadok et al., 2001; Ferraro-Peyret et al., 2002).  
Extrinsic apoptosis is initiated when extracellular pro-apoptotic ligands 
activate transmembrane death receptors embedded in the cell surface. For 
example, the Fas Ligand (FasL) activates the Fas Receptor (FasR), while Tumor 
Necrosis Factor (TNF-α) activates the Tumor Necrosis Factor Receptor 1 
(TNFR1). These death receptors are part of the TNF superfamily of receptors, 
and they contain a cysteine-rich domain exposed outside the cell and a death 
domain facing inward (Ashkenazi and Dixit, 1998; Locksley et al., 2001). Upon 
binding of ligands to receptors, the death domains of the receptors interact with 
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and activate adaptor proteins inside the cell (Grimm et al., 1996; Hsu et al., 
1995), forming the death-inducing signaling complex (DISC). This complex 
induces auto-catalytic cleavage of pro-Caspase-8, leading to activation of 
Caspase-8 followed by subsequent cleavage and activation of executioner 
Caspases (Kischkel et al., 1995).   
 This research presented here will focus on the role of proteins that 
mediate the intrinsic apoptotic pathway (Figure 1-1), which can be activated by 
diverse stimuli such as UV radiation, ionizing radiation, and other forms of DNA 
damage as well as hypoxia, cytotoxic drugs, viral infections, and oxidative stress. 
During intrinsic apoptosis, cellular stressors such as DNA damage lead to 
mitochondrial outer membrane permeabilization (MOMP), releasing cytochrome 
c and other factors from the mitochondrial intermembrane space. Upon its 
release into the cytosol, cytochrome c interacts with APAF-1 and Caspase-9 to 
form the apoptosome, leading to auto-activation and cleavage of Caspase-9 and 
subsequent activation of Caspase-3, Caspase-7, and downstream targets. This 
process can also be regulated by other proteins released from the mitochondria 
during MOMP, such as XIAP, DIABLO/SMAC, and HtrA2/OMI (Du et al., 2000; 
Duckett et al., 1996; Faccio et al., 2000; Tait and Green, 2010; Verhagen et al., 
2000).  
Mitochondrial outer membrane permeabilization (MOMP) is regulated 
primarily by the BCL-2 family of proteins—a large group of both pro-apoptosis 
and pro-survival proteins, the balance of which determines a cell’s fate (reviewed 
recently by (Chipuk et al., 2010) and (Youle and Strasser, 2008)). The anti-
9 
apoptotic protein BCL-2 (B-cell lymphoma 2) was the first family member to be 
identified, after expression of the BCL-2 gene was discovered to be altered in B-
cell follicular lymphomas following a chromosomal translocation between 
chromosomes 14 and 18. This translocation places the gene behind an 
immunoglobulin heavy chain promoter and enhancer, leading to excessive 
transcription of BCL-2, thereby allowing the cell to evade apoptosis (Bakhshi et 
al., 1985; Cleary et al., 1986; Tsujimoto et al., 1985; Vaux et al., 1988).  The 
finding that BCL-2’s anti-apoptotic function promotes carcinogenesis established 
a paradigm for apoptosis as a tumor suppressor mechanism, and evasion of 
apoptosis is now widely accepted as a hallmark of cancer (Hanahan and 
Weinberg, 2000). The BCL-2 family now contains at least twenty identified 
members, all of which share one or more of four BCL-2 homology domains (BH1-
4) (Youle and Strasser, 2008). The anti-apoptotic BCL-2 family members include 
BCL-2, BCL-XL, BCL-W, A1A, and MCL-1 and contain anywhere from two to four 
BH domains.  Pro-apoptotic BCL-2 proteins include BAX and BAK, each of which 
contains BH1, BH2, and BH3 domains, and which permeabilize the mitochondrial 
outer membrane (MOM) during apoptosis. Another set of pro-apoptotic BCL-2 
family members known as the “BH3-only” proteins activate apoptosis by 
antagonizing the function of anti-apoptotic members and/or by directly activating 
pro-apoptotic BAX or BAK; these include BAD, BIK, BID, HRK, BIM, BMF, 
NOXA, and PUMA, all of which share a BH3 domain but have little sequence or 
structural similarity to the other BCL-2 family members aside from this domain. 
10 
The BCL-2 family members’ functions and domains are summarized in Figure 1-
2.   
 The mitochondrial outer membrane is permeabilized directly by effector 
proteins BAX and/or BAK (Figure 1-3). BAX continually cycles between the 
mitochondria and cytosol, while BAK is constitutively localized to the 
mitochondria. In healthy cells, BAX is retro-translocated from the mitochondria to 
the cytoplasm by BCL-XL, but during apoptosis, the interaction between BCL-XL 
and BAX is disrupted, and BAX accumulates at the mitochondria (Edlich et al., 
2011). Upon induction of apoptosis, both BAX and BAK undergo conformational 
changes to become “activated” and oligomerize on the mitochondrial outer 
membrane (Wei et al., 2001), leading to membrane permeabilization through a 
mechanism that is not yet clear but that may occur through formation of a 
proteinaceous or lipid pore (Chipuk and Green, 2008). Rather than being evenly 
distributed around the mitochondria, active BAX accumulates in massive clusters 
at the ends of mitochondria or co-localized with mitochondrial fission and fusion 
sites (Karbowski et al., 2002), leading to the proposal that BAX may either hijack 
the fission/fusion machinery and/or take advantage of the altered mitochondrial 
membrane structure at these sites in order to permeabilize the membrane. The 
exact biochemical mechanism by which BAX and BAK permeabilize the 
membrane is currently an area of intense investigation and has been described 
as one of the “holy grails” of apoptosis research (Youle and Strasser, 2008).  
BAX and BAK become activated during apoptosis by pro-apoptotic BH3-
only BCL-2 family proteins such as BIM, BID, and PUMA (Chipuk et al., 2005; 
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Gavathiotis et al., 2010; Kim et al., 2006; Kim et al., 2009; Kuwana et al., 2005; 
Letai et al., 2002; Lovell et al., 2008; O'Connor et al., 1998; Ren et al., 2010; Wei 
et al., 2000). Conversely, the pro-apoptotic function of BAX and BAK can be 
inhibited by pro-survival BCL-2 family proteins such as BCL-xL, MCL-1, and 
BCL-2 itself (Boise et al., 1993; Chipuk et al., 2010; Kozopas et al., 1993; Oltvai 
et al., 1993). The precise mechanisms by which BCL-2 family members interact 
to mediate apoptosis are still under debate, and several models have been 
proposed that are not necessarily mutually exclusive (Chipuk et al., 2010) (Figure 
1-4).  
The direct activation model proposes that pro-apoptotic BH3-only proteins 
bind directly to BAX or BAK to induce their activation, and that the role of anti-
apoptotic proteins in healthy cells is to bind and sequester BH3-only proteins to 
prevent them from activating BAX and BAK. Several BH3-only proteins are 
capable of directly activating BAX and/or BAK in isolated mitochondria or large 
unilamellar vesicles (LUVs) meant to mimic the mitochondrial outer membrane. It 
is difficult to detect an interaction between in BAX or BAK and BH3-only proteins 
in vivo, likely because the interaction is thought to be transient. However, a 
recent study utilizing a mouse model in which the genes encoding BIM, BID, and 
PUMA were simultaneously deleted demonstrated that at least one of these 
“direct activator” proteins is necessary for activation of BAX and BAK in vivo (Ren 
et al., 2010).  
Other BH3-only proteins, such as BAD, BIK, HRK, and NOXA, cannot 
directly activate BAX or BAK and are thought to function by binding with, and 
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thereby deactivating, anti-apoptotic proteins such as BCL-2 and BCL-xL (Chen et 
al., 2005; Chipuk et al., 2008; Kuwana et al., 2005; Letai et al., 2002). These 
BH3-only proteins may act as either sensitizers or de-repressors for the effector 
proteins. The sensitization model purports that the interaction between BH3-only 
proteins and anti-apoptotic BCL-xL or BCL-2 would not induce apoptosis, but 
would sensitize cells to apoptotic stimuli. In this scenario, BAX or BAK would still 
require direct activation by BIM, BID, or PUMA, but the “sensitizer” BH3-only 
proteins would deactivate the anti-apoptotics (e.g. BCL-2), preventing inhibition 
of the direct activators. In this way, the sensitizer BH3-only proteins would lower 
the threshold for BAX and BAK activation (Chipuk et al., 2010).  
According to the derepression model, direct activator proteins (e.g. BIM or 
BID) are bound and sequestered by anti-apoptotic proteins (e.g. BCL-xL or BCL-
2). During apoptosis, a derepressor BH3-only protein such as BAD competes 
with the direct activator for binding with the anti-apoptotic protein, releasing the 
direct activator. The direct activator is then free to interact with and activate BAX 
or BAK (Chipuk et al., 2010). This model is supported by in vitro FRET 
(fluorescence resonance energy transfer) studies using LUVs; in the presence of 
these membranes, anti-apoptotic BCL-xL was bound with the direct-activator 
BID. Introduction of the derepressor BAD disrupted the BCL-xL-BID complex, 
freeing BID to directly interact with and activate BAX, leading to permeabilization 
of the LUV (Lovell et al., 2008). Furthermore, when a pharmacological 
derepressor BH3 mimetic was used to treat chronic lymphocytic leukemia (CLL), 
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mitochondrial outer membrane permeabilization was induced (Certo et al., 2006; 
Del Gaizo Moore et al., 2007).  
Finally, a neutralization model has been proposed in which the effector 
proteins BAX and BAK are always active but are sequestered by anti-apoptotic 
proteins such as BCL-2 or BCL-xL. For apoptosis to occur, BH3-only proteins 
compete for binding with the anti-apoptotic proteins, releasing the already-active 
BAX or BAK. According to this model, direct activator BH3-only proteins are not 
required for apoptosis; release of the effector proteins from their inhibitors is 
sufficient to activate apoptosis.  
One difficulty in reconciling these contradictory models is that many of the 
studies examining the interactions between BCL-2 family members are based on 
in vitro experiments such as those involving isolated mitochondria or artificial 
LUVs, and many have utilized extensive ectopic expression of tagged proteins. 
These types of studies do not always recapitulate what occurs in a live cell in 
vivo; other proteins and lipids present in a live cell are likely to be important, as 
are stoichiometric ratios among BCL-2 family members. Two recent studies have 
partially resolved this issue by providing evidence that a direct activator protein is 
required for BAX and BAK to induce MOMP in vivo. In one study, mice were 
generated in which the BH3 domain of BIM was replaced by BAD, NOXA, or 
PUMA (Merino et al., 2009). In another, BIM, BID, and PUMA were knocked out 
simultaneously (Ren et al., 2010). Both of these genetic approaches 
demonstrated that direct activator proteins are necessary for BAX and BAK 
activation, BAX oligomerization, MOMP, and apoptosis in vivo. It is likely that in 
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intact cells, apoptosis is regulated by a combination of these models; 
sensitization and direct activation probably both contribute. As induction of 
MOMP is often a life-or-death decision for a cell, it is logical for it to be regulated 
by a complex mechanism. For example, one subset of BH3-only proteins may be 
required for direct activation of BAX and BAK, while another subset of sensitizing 
or derepressing BH3-only proteins must interact with anti-apoptotic proteins such 
as BCL-2 and BCL-xL to release their inhibition of the effector proteins.  
Aside from BCL-2 family members, a handful of unrelated proteins have 
been found to regulate MOMP. Some of these proteins, while not considered 
BCL-2 family members, do contain a putative BH3 domain. These include MAP-1 
and RAD9 (a DNA repair protein), which can directly activate BAX and BAK 
(Chipuk et al., 2010). Other proteins that do not have any known homology to the 
BCL-2 family are also reported to regulate apoptosis either through direct 
activation of BAX or BAK, or by interaction with anti-apoptotic BCL-2 family 
members. The transcription factor Nur77 is reported to convert BCL-2 from an 
anti-apoptotic to a pro-apoptotic protein (Thompson and Winoto, 2008). The 
tumor suppressor p53, which transcriptionally upregulates pro-apoptotic proteins 
following DNA damage, also interacts directly with BAX to induce its activation. 
Furthermore, p53 is reported to be sequestered by anti-apoptotic BCL-2 proteins 
and may also have a derepressor role (Chipuk et al., 2004; Leu et al., 2004; 
Marchenko et al., 2000; Mihara et al., 2003). Other non-BCL-2 inducers of 
MOMP include nucleophosmin, ASC, and ATG5 (reviewed by (Chipuk et al., 
2010)). However, data from a triple knockout mouse model lacking BIM, BID, and 
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PUMA, in which activation of BAX and BAK did not occur, suggests that these 
non-BCL-2 proteins may not always be sufficient in vivo to induce BAX- or BAK-
mediated apoptosis (Ren et al., 2010). VDAC2 can regulate MOMP by binding to 
BAK, restraining it in an inactive monomer conformation. The following non-BCL-
2 proteins are also reported to regulate MOMP through mechanisms that are 
unclear: Histone H1.2, 14-3-3θ , Ku70, and BRCC2 (reviewed by (Chipuk et al., 
2010)). 
 Mitochondria themselves are not passive bystanders in their 
permeabilization during apoptosis. Components of the membrane are known to 
be important, as BAX and t-BID fail to interact in the absence of natural or 
artificial membranes (Lovell et al., 2008). Recently, mitochondrial dynamics have 
emerged as another means by which MOMP may be regulated (Martinou and 
Youle, 2011). In healthy cells, individual mitochondria continually fuse and divide. 
Fusion is regulated primarily by Mitofusin proteins 1 and 2 (MFN1, MFN2). 
Mitofusins located on adjacent mitochondria dimerize, anchoring mitochondria 
together to initiate the fusion process (Chen et al., 2003; Santel and Fuller, 
2001). Fission is mediated largely by dynamin-related protein 1 (DRP1), 
(Karbowski et al., 2002; Labrousse et al., 1999; Otsuga et al., 1998; Smirnova et 
al., 2001). Fission and fusion occur continuously, and if the balance between 
these two processes is altered, aberrant mitochondrial structure results. With an 
excess of fusion, mitochondria become elongated and form networks, while 
overabundant fission causes mitochondria to fragment into smaller, yet intact, 
organelles.  
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Mitochondrial fragmentation occurs during apoptosis prior to cytochrome c 
release (Brooks et al., 2007; Lee et al., 2004), and evidence has accumulated to 
support the idea that fragmentation plays an active role in MOMP. Inhibition of 
fusion-promoting proteins MFN1 or MFN2 causes mitochondria to become 
fragmented and sensitizes cells to MOMP and apoptosis (Sugioka et al., 2004), 
while overexpression of MFN1 or MFN2 reduces fragmentation and protects cells 
from apoptosis (Brooks et al., 2011). Additionally, a chemical inhibitor of fission, 
Mdivi-1, as well as fusion-inducing cysteine alkylators and N-ethyl-maleimide 
(NEM), partially inhibit fragmentation, MOMP, and apoptosis (Bowes and Gupta, 
2005; Cassidy-Stone et al., 2008). Likewise, inhibition of fission-mediating DRP1 
by RNAi or by introducing dominant-negative mutations in the GTPase domain 
partially inhibits mitochondrial fragmentation while delaying MOMP and apoptosis 
(Brooks et al., 2011; Frank et al., 2001). Furthermore, a recent study showed 
compelling evidence that DRP1 modulates apoptosis by altering mitochondrial 
dynamics, stimulating BAX oligomerization (Montessuit et al., 2010).  
 
Unknowns in Field of Apoptosis Research  
 While much has been learned about mechanisms and signaling pathways 
regulating apoptosis, especially the roles of pro- and anti-apoptotic BCL-2 family 
proteins, our understanding is incomplete in several areas. Many of the non-BCL-
2 proteins’ specific biochemical mechanisms in regulating apoptosis are 
unknown, and additional proteins that regulate apoptosis remain to be identified. 
Currently, much research is focused on the mechanisms regulating MOMP, as 
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this process is often the point of no return for deciding a cell’s fate. More 
specifically, controversy still exists regarding the competing models (direct 
activation, sensitization, derepression, and neutralization) for interactions among 
BCL-2 family members in regulating MOMP. There is also a high level of interest 
in elucidating the precise biochemical mechanisms by which BAX and BAK 
permeabilize the mitochondrial outer membrane (i.e. through formation of a 
protein or lipid pore, or an alternate mechanism). Gaining a better understanding 
of these processes will contribute to our knowledge of organismal development 
and homeostasis and may aid in the design of targeted therapeutic drugs to treat 
diseases affected by aberrant regulation of apoptosis, such as autoimmune 
disorders, neurodegenerative disease, and cancer.  
 
p32/C1QBP: a Multifunctional Protein Recently Identified as a Regulator of 
Apoptosis 
Previous work in our laboratory ((Itahana and Zhang, 2008) and 
unpublished data) uncovered a critical role for the mitochondria-localized non-
BCL-2 protein p32 in regulating apoptosis. This multifunctional protein (also 
known as GC1QR for receptor for C1q; HABP1 for hyaluronic acid binding 
protein 1; C1QBP for globular head component factor C1q binding protein) is 
thought to be localized primarily in the mitochondrial matrix (Dedio et al., 1998; 
Muta et al., 1997). p32 is reported to interact with complement component C1q 
(Ghebrehiwet et al., 1994), may play roles in RNA splicing (Petersen-Mahrt et al., 
1999) and oxidative phosphorylation (Muta et al., 1997), and was recently 
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reported to mediate apoptotic response (Chowdhury et al., 2008; Kamal and 
Datta, 2006).  
Our laboratory discovered a novel role for p32 in regulating ARF-mediated 
apoptosis through regulation of mitochondrial membrane potential prior to MOMP 
(Itahana and Zhang, 2008), and a second role for p32 downstream of MOMP 
following release of mature, cleaved p32 from the mitochondria (Itahana and 
Zhang, unpublished data). However, a precise biochemical mechanism for the 
function of p32 in these two roles was lacking. In order to learn more about the 
mechanism of p32 in regulating apoptosis, we sought to identify novel binding 
partners for p32. Thus, a large-scale co-immunoprecipitation was carried out for 
p32, and potential p32-interacting partners were identified by mass spectrometry. 
Of these, we selected two uncharacterized proteins for further study: MAGE-D2 
(melanoma antigen family D2) and SUMI-1 (survival-promoting mitochondrial 
protein 1, also known as CHCHD2 for coiled-coil-helix coiled-coil-helix domain-
containing 2). While the initial rationale for identifying novel p32-interacting 
proteins was to provide a means to better understand the mechanism of p32’s 
apoptotic functions, we opted instead to study MAGE-D2 and SUMI-1 individually 
prior to pursuing studies regarding their interaction with p32. In this body of work, 
the research performed to characterize these two proteins’ localization and 
functions will be presented. In Chapter VI, future experiments are proposed for 
examining the function of these proteins’ interactions with p32.  
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Figure 1-1. Key signaling molecules in the intrinsic apoptosis pathway. 
This illustration depicts a simplified version of key signaling events in the intrinsic 
(mitochondria-mediated) apoptosis pathway. During apoptosis, an important 
regulatory event is mitochondrial outer membrane permeabilization (MOMP). 
MOMP is regulated primarily by pro- and anti-apoptotic BCL-2 family proteins. 
Upon treatment with apoptotic stimuli such as UV radiation, pro-apoptotic 
proteins are induced, leading to activation and oligomerization of pro-apoptotic 
effector proteins BAX and/or BAK. Oligomerization of these effectors induces 
MOMP, causing release of mitochondrial intermembrane space proteins such as 
cytochrome c into the cytosol. Cytochrome c then interacts with APAF-1 and 
Caspase-9 to form the apoptosome, leading to Caspase-9 auto-cleavage and 
activation. Active Caspase-9 then cleaves and activates Caspase-3, leading to 
cleavage of CAD, PARP, and other downstream targets to induce apoptosis.  
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Figure 1-2. Functional organization and general domain structure of BCL-2 
family proteins. 
BCL-2 family members can be divided into four categories according to function, 
as shown. BH (BCL-2 homology) domains and TM (transmembrane) domains 
that are present among most members of each category are indicated. 
Illustrations are not to scale.  
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Figure 1-3. Regulation of mitochondrial outer membrane permeabilization 
(MOMP) by BAX and BAK. 
A) In healthy cells, BAX continually cycles between the cytosol and mitochondria, 
with the majority of BAX existing in a soluble, cytosolic form. BCL-xL promotes 
retro-translocation of BAX to the cytosol. During apoptosis, BCL-xL is inhibited, 
allowing BAX to accumulate at the mitochondria. Upon activation by BH3-only 
proteins, BAX undergoes a conformational change and subsequently 
oligomerizes, inducing MOMP and cytochrome c release.  
B) BAK is constitutively localized to the mitochondria. During apoptosis, BAK is 
activated by BH3-only proteins, leading to BAK oligomer formation and MOMP. 
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Figure 1-4. Competing models of apoptosis regulation by BCL-2 family 
proteins. 
The direct activation model proposes that specific BH3-only proteins can directly 
interact with and activate the effector proteins BAX and BAK. The sensitization 
model says that certain BH3-only proteins can bind to and inactivate anti-
apoptotic proteins, releasing their inhibition of BAX and BAK, thereby sensitizing 
cells to apoptosis. According to the derepressor model, anti-apoptotic proteins 
bind and sequester direct-activator BH3-only proteins, preventing their activation 
of BAX and BAK. When activated, the effector proteins BAX and BAK induce 
MOMP and cytochrome c release, leading to apoptotic cell death. 
 
  
 
 
 
 
 
CHAPTER II 
IDENTIFICATION OF MAGE-D2 AND SUMI-1 AS NOVEL INTERACTING 
PARTNERS FOR THE PRO-APOPTOTIC PROTEIN P32/C1QBP 
 
Introduction  
Recently, our lab uncovered novel roles for the multifunctional protein 
p32/C1QBP in regulating apoptosis by two distinct mechanisms. First, p32 was 
found to be required for apoptosis induced by the tumor suppressor ARF 
(Itahana and Zhang, 2008). Later, p32 was found to be a critical mediator for 
apoptosis induced by a broad range of stimuli (unpublished data). Thus, p32 
regulates apoptosis by two mechanisms: 1) It recruits ARF to the mitochondria, 
where ARF induces a change in mitochondrial membrane potential (∆Ψm), 
sensitizing cells to apoptosis (Itahana and Zhang, 2008), and 2) Once released 
into the cytoplasm, mature (cleaved) p32 activates Caspase-9 and Caspase-3 to 
induce apoptosis (unpublished data). However, the exact mechanisms by which 
p32 induces apoptosis have been elusive. One means by which a protein’s 
functional mechanisms can be elucidated is through identification of novel 
interacting proteins. Thus, in order to learn more about this novel critical regulator 
of apoptosis, we performed a screen to search for previously unknown p32 
binding partners.   
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Screen for Novel p32-Interacting Proteins 
 In order to identify potential novel interacting partners for p32, a large-
scale co-immunoprecipitation was carried out for Flag-tagged p32. First, cell lines 
were generated to express p32-Flag in a stable manner. U2OS (human 
osteosarcoma) cells were transfected with a pcDNA3-p32-Flag plasmid, and 
clones expressing the plasmid were selected for with the antibiotic G418. Clones 
stably-expressing p32-Flag were obtained, and expression of p32-Flag was 
confirmed by western blotting (Figure 2-1). Correct mitochondrial localization of 
p32-Flag was confirmed by immunofluorescence imaging, as indicated by co-
localization with the mitochondria-labeling dye MitoTracker™ Red (Figure 2-2). 
 A large-scale co-immunoprecipitation (co-IP) was then carried out with the 
p32-Flag stable cell lines, using mock-transfected U2OS cells as a negative 
control. Fifteen 100-mm plates of each cell type were lysed with 0.1% NP-40 
lysis buffer, and a co-IP was performed using gel beads pre-conjugated with Flag 
antibody in order to pull down protein complexes containing p32-Flag. These 
complexes were resolved by SDS-PAGE, and the resulting gel was stained with 
Coomassie Brilliant Blue to visualize bands representing potential p32 binding 
partners (Figure 2-3). Each band was subjected to mass spectrometry to identify 
the proteins likely to be present in the band. A list of bands identified, 
representing potential p32 interacting partners, is shown in Table 2-1.  
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Selection of MAGE-D2 and SUMI-1 for Further Study 
 After careful examination of the eight putative p32-interacting proteins 
identified, two were selected for further study: MAGE-D2, an uncharacterized 
melanoma antigen family protein, and SUMI-1, an uncharacterized protein 
predicted to localize to the mitochondria.   
MAGE-D2 was selected primarily because its close homolog, 
NRAGE/MAGE-D1 is known to regulate apoptosis (Barker and Salehi, 2002; 
Chomez et al., 2001). The MAGED genes, including MAGE-D1 and MAGE-D2, 
are clustered on chromosome Xp11, and the gene encoding MAGE-D2 is located 
at Xp11.2, a hot spot for X-linked mental retardation. Unlike the initially-
discovered MAGE family members, whose expression is detected only during 
embryonic development and in tumor cells, MAGE-D2 is ubiquitously expressed 
in adult tissues (Langnaese et al., 2001). No studies have been published 
regarding the function of MAGE-D2, but its expression has been linked to cancer 
initiation and/or progression. MAGE-D2 overexpression is associated with small-
intestinal carcinoid neoplasia (Kidd et al., 2006a) and with progression of gastric 
neoplasia, and the level of MAGE-D2 differentiates Type III/IV gastric neoplasias 
from Type I/II (Kidd et al., 2006b). MAGE-D2 upregulation is also linked to liver 
metastasis of colon cancer (Li et al., 2004). A close homolog of MAGE-D2—
NRAGE/MAGE-D1—was reported to interact with the p75 neurotrophin receptor 
to promote nerve growth factor-dependent apoptosis (Salehi et al., 2000). 
NRAGE can also interact with the apoptosis inhibitory factor XIAP (X-linked 
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inhibitor of apoptosis) and appears to accelerate degradation and inactivation of 
XIAP during apoptosis (Jordan et al., 2001).  
 SUMI-1 is a small, CHCH domain-containing protein, and no studies 
regarding its functions were published when we began our research on this 
protein. SUMI-1 was selected for further study primarily because another protein 
reported to be a mouse ortholog of SUMI-1 (NDG1; Nur77 downstream gene 1) 
was shown to regulate apoptosis after induction by the nuclear steroid orphan 
receptor Nur77 (Rajpal et al., 2003). However, upon further investigation, this 
protein was found not to be a direct ortholog of SUMI-1 as reported. In addition, 
unlike the majority of putative p32-interacting proteins identified, SUMI-1 was 
predicted to localize to the mitochondrion (Claros and Vincens, 1996), an 
organelle with strong ties to apoptotic cell death.  
 
Confirmation of Binding Between p32-SUMI-1 and p32-MAGE-D2 
 To determine whether MAGE-D2 and SUMI-1 represent genuine binding 
partners for p32, additional co-immunoprecipitation experiments were carried out. 
U2OS cells were transfected with p32-Flag, Myc-SUMI-1, and/or Myc-MAGE-D2 
and immunoprecipitated for Flag to pull down p32-Flag-containing complexes. 
Samples were resolved by SDS-PAGE and blotted for Myc or Flag, where 
indicated. Binding was confirmed between p32-Flag and SUMI-1-Myc, with no 
signal detected in cells not transfected with p32-Flag, indicating that SUMI-1-Myc 
did not interact nonspecifically with the Flag antibody. A strong interaction was 
also confirmed between p32-Flag and MAGE-D2-Myc. A small amount of signal 
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was detected in the negative control lane, which likely represents spillover from 
another lane and/or incomplete washing of beads; however, a dramatically higher 
signal was detected in cells transfected with p32-Flag, despite lower expression 
of MAGE-D2-Myc (see loading panel), indicating that MAGE-D2-Myc does 
interact nonspecifically with the Flag antibody (Figure 2-4). Thus, we detected 
binding of ectopically expressed p32 with both SUMI-1 and MAGE-D2 
 Interaction of endogenous proteins was also examined. Untreated U2OS 
cell lysates were immunoprecipitated for SUMI-1 or MAGE-D2, using two 
different antibodies for each protein. Samples were resolved by SDS-PAGE and 
blotted for SUMI-1, MAGE-D2, and p32. One SUMI-1 antibody successfully 
immunoprecipitated SUMI-1, and p32 was also detected in this lane, 
demonstrating endogenous SUMI-1-p32 binding. Both MAGE-D2 antibodies 
were capable of pulling down MAGE-D2 and also immunoprecipitated p32, albeit 
with lower affinity than that of the SUMI-1-p32 interaction (Figure 2-5).  Thus, the 
p32-SUMI-1 and p32-MAGE-D2 interactions were both confirmed in three ways: 
1) Immunoprecipitation of ectopic p32 and detection of endogenous SUMI-1 and 
MAGE-D2 by mass spectrometry, 2) IP of ectopically-expressed proteins and 
detection with Flag and Myc antibodies, and 3) IP of endogenous proteins in 
untransfected cells and detection with antibodies toward endogenous proteins.  
 
Materials and Methods 
Cell culture, transfections, and generation of stable cell lines. U2OS cells 
were obtained from ATCC and cultured in a 37°C incubator with 5% CO2 in 
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DMEM supplemented with 10% FBS, 100 U/ml penicillin, and 100 g/ml 
streptomycin. DNA transfections were carried out with Effectene® (Qiagen) 
according to the manufacturer’s instructions. Cells were transfected with 
pcDNA3-p32-Flag or pcDNA3 vector and subject to selection with G418. 
Individual clones were isolated and cultured, and expression of p32-Flag was 
examined by immunofluorescence staining and/or western blotting.  
 
Co-immunoprecipitation, SDS-PAGE, and western blotting. For co-immuno-
precipitations (co-IP), cells were lysed in 0.1% NP-40 lysis buffer, pre-cleared for 
30 minutes with CL-4 beads, and incubated in primary antibody for 4 hours to 
overnight followed by incubation in Protein A beads for 1 hour. Beads were 
washed 3x and protein complexes were eluted using 1x SDS-PAGE sample 
buffer. For the large-scale co-IP, cells were treated as above but incubated in 
beads pre-conjugated with Flag antibody (ANTI-FLAG® M2 Affinity Gel, Sigma). 
Where indicated, a portion of lysate was reserved prior to IP and used as a 
loading control. Beads were washed 3x, and 1x-SDS sample buffer was added to 
remove protein complexes from beads. IP samples and loading controls were 
resolved by SDS-PAGE with a 12.5% or 15% polyacrylamide gel and transferred 
onto a 0.2 µM nitrocellulose membrane. Membranes were blocked for a minimum 
of 30 minutes in phosphate-buffered saline buffer with 0.1% Tween-20 (PBST) 
and 5% nonfat dried milk. Membranes were incubated for 2h to overnight in 
primary antibody, incubated for 1-2 hours in secondary HRP-conjugated 
antibody, and exposed with Supersignal West Pico (Pierce).  
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DNA Plasmids. C-terminally Flag-tagged p32, N-terminally Myc-tagged SUMI-1, 
and N-terminally Myc tagged MAGE-D2 were cloned into a pcDNA3.1 vector 
(Invitrogen) and confirmed by restriction digest and DNA sequencing.  
 
Antibodies. Monoclonal mouse ANTI-FLAG® M2 antibody was purchased from 
Sigma. Rabbit anti-Myc antibody was purchased from Abcam. Rabbit anti-SUMI-
1 (94, 124) and rabbit anti-MAGE-D2 (180, 262) antibodies were used for 
endogenous co-IP.  
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Figure 2-1. Clones stably expressing p32-Flag. 
Western blot showing expression of p32-Flag fusion protein, detected with Flag 
antibody, in whole cell extracts of three U2OS clones stably transfected with p32-
Flag plasmid. Untransfected U2OS cell lysate was used as a negative control.  
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Figure 2-2. U2OS cells stably expressing p32-Flag. 
Immunofluorescence imaging shows that p32-Flag in stably-transfected U2OS 
cells is correctly localized to the mitochondria, as indicated by staining with 
MitoTracker® Red. 
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Figure 2-3. Large-scale co-immunoprecipitation of p32. 
U2OS (human osteosarcoma) cells stably transfected with empty plasmid 
(Vector) or p32-Flag were lysed with 0.1% NP-40 lysis buffer and incubated with 
Flag-conjugated beads. Immunoprecipitated complexes were resolved by SDS-
PAGE and visualized with Coomassie Blue staining. Bands that are present in 
p32-Flag IP but not the vector-only control represent putative p32-interacting 
proteins and were analyzed by mass spectrometry. Bands representing MageD2 
and SUMI-1 are indicated. Other identified bands are shown in Table 2-1.  
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Table 2-1. Potential p32-interacting proteins. 
Bands identified by mass spectrometry following a large-scale co-
immunoprecipitation of p32-Flag in stably-transfected U2OS cells.  
 
 
 
  
Protein Function 
ZFP91 (zinc finger protein 91 
homologue) 
Putative transcription factor; upregulated in 
acute myeloid leukemia (Unoki et al., 2003) 
NO66 (nucleolar protein 66) 
Ribosomal biogenesis, chromatin remodeling 
(Eilbracht et al., 2004) 
MAGE-D2 (melanoma antigen 
family D2) 
Uncharacterized; homolog MAGE-D1 regulates 
apoptosis (Chomez et al., 2001) 
YB1 (Y-box binding protein 1) 
Transcription factor; regulates cell cycle 
(Jurchott et al., 2003) 
ALY-THOC4 (THO complex 
subunit 4) 
Transcriptional co-activator; couples 
transcription to mRNA export (Bruhn et al., 
1997; Luo et al., 2001)  
Ribosomal protein S7 Translation of proteins (Annilo et al., 1995) 
SUMI-1/CHCHD2 Uncharacterized 
Ribosomal protein S17 Translation of proteins (Chen and Roufa, 1988) 
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Figure 2-4. Confirmation of p32-MAGE-D2 and p32-SUMI-1 binding.  
Western blots showing interaction between ectopically-expressed proteins. 
U2OS cells were transfected with p32-Flag and either SUMI-1-Myc or  MAGED2-
Myc where indicated. Lysates were immunoprecipitated with Flag antibody and 
resolved by SDS-PAGE. IP is shown in panel on left, and loading is shown on 
right. 
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Figure 2-5. Endogenous binding between p32-MAGED2 and p32-SUMI-1.  
Western blot showing interaction between endogenous proteins. Lysates from 
untransfected U2OS cells were immunoprecipitated with indicated antibodies 
(IgG, negative control) and resolved by SDS-PAGE. Loading is shown on left. 
Note that the SUMI-1-94 antibody is effective for immunoprecipitation, while the 
SUMI-1-124 is not. MAGE-D2 could be immunoprecipitated with both antibodies, 
and a p32 band could be observed for each MAGE-D2 IP.  
 
 
  
 
 
 
 
 
 
CHAPTER III 
 
 
LOCALIZATION AND FUNCTIONAL STUDIES OF THE UNCHARACTERIZED 
MELANOMA ANTIGEN FAMILY PROTEIN, MAGE-D2 
 
Introduction and Background 
 The initial members of the human MAGE (melanoma antigen family) 
genes to be identified are silent in normal adult tissues and expressed only in the 
male germ line and tumor cells. These proteins—the MAGE-A, MAGE-B, and 
MAGE-C subfamilies—are located in clusters on the X chromosome and are 
each encoded by a single exon. Because of their tumor-specific expression, 
these proteins have generated interest as potential targets for cancer 
immunotherapy. Now, the MAGE family has been expanded to include more than 
25 members, and some of these are expressed in normal tissues (Chomez et al., 
2001). Among these are the MAGE-D subfamily, comprised of MAGE-
D1/NRAGE, MAGE-D2, MAGE-D3, and MAGE-D4, each of which contains both 
a MAGE homology domain (MHD, or MHD I) and a MAGE homology II domain 
(MHD II). The MHD is found in all MAGE proteins, while the MHD II is shared 
only by Type II MAGE proteins, which include MAGE-D1-4, MAGE-E1, and 
MAGE-L2. The MAGE-D subfamily is also unique from the MAGE-A, -B, and -C 
families in that each member is encoded by multiple exons rather than a single 
exon (Chomez et al., 2001). The functions of MAGE family proteins are not well-
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known, although roles have been uncovered for Type II MAGE proteins in cell 
survival, cell cycle progression, and apoptosis (Barker and Salehi, 2002). 
Because there is known to be extensive functional redundancy among 
MAGE proteins, examination of other MAGE-D family members can yield clues to 
potential functions and mechanisms for MAGE-D2. Of the MAGE-D subfamily, 
only MAGE-D1 has been well-characterized. MAGE-D1 shares 41% amino acid 
identity with MAGE-D2 and has been reported to regulate apoptosis through 
several mechanisms. MAGE-D1 interacts with the p75 neurotrophin receptor 
(p75NTR), which is a member of the TNF (tumor necrosis factor) family of 
proteins, and co-expression of MAGE-D1 with p75NTR greatly enhances 
neurotrophin-receptor-mediated apoptosis (Salehi et al., 2000). Overexpression 
of MAGE-D1 alone was also found to be sufficient to induce apoptosis (Barker 
and Salehi, 2002; Salehi et al., 2000) by activating c-Jun N-terminal kinase 
(JNK), leading to phosphorylation of c-Jun, release of cytochrome c, and 
Caspase activation (Salehi et al., 2002). MAGE-D1 also interacts with several 
homeodomain family transcription factors that regulate development through 
control of cell cycle and apoptosis—Msx2, Dlx7, and Dlx5—and MAGE-D1 was 
shown to be required for Dlx5-dependent transcription (Masuda et al., 2001). 
MAGE-D1 has also been identified as a binding partner for the anti-apoptotic 
proteins XIAP and ITA, both members of the IAP (inhibitor of apoptosis) family of 
proteins (Jordan et al., 2001). IAP proteins block apoptotic cell death by binding 
to and inhibiting activated Caspases. MAGE-D1 appears to interact with XIAP to 
accelerate apoptosis induced by IL-3 withdrawal in IL-3-dependent 32D cells. 
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The exact mechanism is unclear but appears to involve formation of a transient 
complex between MAGE-D1 and XIAP that may lead to XIAP’s degradation and 
inactivation (Jordan et al., 2001). MAGE-D1-induced apoptosis and cell cycle 
arrest have both been shown to require activation of the tumor suppressor p53 
(Kendall et al., 2005; Wen et al., 2004), which is contrary to the roles of several 
anti-apoptotic Type I MAGE proteins that have been shown to inhibit p53’s 
transcriptional activity (Doyle et al., 2010; Marcar et al., 2010; Monte et al., 2006; 
Yang et al., 2007).  
 MAGE-D2 is not well-characterized but has been identified in several 
screens for genes with altered expression in cancers. The gene encoding MAGE-
D2 is located at chromosome Xp11.2, a hot-spot for x-linked mental retardation, 
and yields 3 known transcripts. The MAGE-D2 protein is encoded by 11 exons 
and contains 606 amino acids, with a predicted molecular weight of 65 kD. It 
contains two known domains, MHD I and MHD II (Figure 3-1), and an arginine-
rich region from aa 215-258. The protein is highly conserved in mammals, with 
87% amino acid identity in mice (mus musculus). In zebrafish (danio rerio) and 
the fruit fly (drosophila melanogaster), a single MAGE gene is orthologous to the 
entire human MAGE family; human MAGE-D2 retains 38% amino acid identity to 
this gene in zebrafish and 24% identity to the fruit fly ortholog (data obtained from 
HomoloGene). Like MAGE-D1, human MAGE-D2 is expressed ubiquitously in 
adult tissues, and its expression is higher in certain brain regions and in the 
interstitium of the testes (Langnaese et al., 2001). In mice, semiquantitative 
mRNA dot-blot analysis revealed the presence of MAGE-D2 transcripts in all 
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adult tissues tested; its expression increases steadily during embryonic 
development, reaching a maximum just before birth; and mouse embryonic 
tissues contain a higher level of MAGE-D2 expression than do adult tissues 
(Chomez et al., 2001). The expression of human MAGE-D2 is elevated in a 
number of cancers including those derived from the breast (fresh breast cancer 
tissue, but not breast cancer cell lines) (Hudelist et al., 2006), appendix (Modlin 
et al., 2006), stomach (Kidd et al., 2006b), and small intestine (Kidd et al., 
2006a). Its overexpression is also associated with cancer progression and 
metastasis—It is elevated 5-10 fold in Type III/IV gastrointestinal cancers but not 
in Type I/II tumors (Kidd et al., 2006b), it is associated with progression of 
appendiceal tumor malignancy (Modlin et al., 2006), and it is expressed to a 
significantly higher degree in colon cancer tumors with liver metastasis than 
those that have not metastasized (Li et al., 2004). 
 The functions of MAGE-D2 are unknown, and no studies have been 
published, to date, regarding its functions. Its elevated expression in cancers and 
association with cancer progression could implicate MAGE-D2 in a variety of 
potential roles such as cell proliferation, evasion of apoptosis, cell migration, or 
cell adhesion. It can be phosphorylated at multiple serine residues (Matsuoka et 
al., 2007; Olsen et al., 2006), and a screen for substrates of ATM and ATR in the 
DNA damage response found that MAGE-D2 is phosphorylated by ATM/ATR at 
specific serine residues (SER-146, SER-162, SER-190, SER-191, and SER-194) 
following DNA damage (Matsuoka et al., 2007), suggesting that it may be an 
effector of the ATM- and ATR-mediated DNA damage response pathway. In this 
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study, we sought to characterize the subcellular localization of MAGE-D2 and 
investigate whether it plays a role in apoptotic cell death. 
  
Generation of Antibodies for Study of Endogenous MAGE-D2 
 When we began our research on MAGE-D2, no antibodies were available 
for biochemical analyses such as western blotting, immunoprecipitation, and 
immunofluorescence staining of endogenous MAGE-D2. In order to carry out 
these studies, we generated two rabbit polyclonal antibodies toward MAGE-D2, 
each targeting a different region of the protein. Various features of the amino acid 
sequence were assessed in order to identify optimal regions of approximately 12-
16 amino acids in length to use as antigens. The most suitable antigens have low 
hydrophobicity (and are, therefore, more likely to be exposed at the protein 
surface), high complexity (e.g. beta-turn tendency), high antigenicity, and minimal 
sequence similarity to other proteins (in order to increase specificity). An 
additional cysteine must be placed on one terminus in order to conjugate the 
peptide to the immunogenic protein, KLH (keyhole limpet cyanin), which 
enhances the immune response in the host. Therefore, no internal cysteines can 
be present in the selected antigen region. Based on careful analysis of the 
MAGE-D2 sequence according to the above parameters, two peptide antigens 
were selected: MD2-180 (corresponding to amino acids 180-194; 
VKHLDGEEDGSSDQS), and MD2-262 (amino acids 262-276; 
LQSSQEPEAPPPRDV) (Figure 3-2). The peptides were sent to PRF&L for 
immunization of rabbits, and serum containing polyclonal antibodies toward the 
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antigens was shipped to our laboratory for purification. Antibodies were affinity-
purified in columns conjugated with the associated peptide antigen and tested in 
our lab by western blotting for effectiveness and specificity. Each antibody 
detected both endogenous and ectopically-expressed MAGE-D2 and was 
specific to MAGE-D2 (Figure 3-3).  
 
MAGE-D2 Localizes to the Mitochondria, Nucleus, and Nucleoli 
 To gain additional clues regarding its functions, we first explored the 
subcellular localization of MAGE-D2. Plasmids were generated for expression of 
N-terminally Myc-tagged, C-terminally Flag-tagged, and C-terminally EGFP-
tagged MAGE-D2 fusion proteins. U2OS cells were transfected with the various 
tagged proteins, and cells were fixed after 18 hours and immunofluorescence 
stained for Myc or Flag. All three proteins were found to localize primarily to the 
nucleoli and the nucleus, with the strongest staining apparent in the nucleoli 
(Figures 3-4 and 3-5). In cells transfected with MAGE-D2-Flag or EGFP-MAGE-
D2, faint staining could also be observed in the cytoplasm. Transfection with 
EGFP-MAGE-D2 appeared toxic to cells, with many transfected cells dying 
(Figure 3-5). Many of the remaining EGFP-MAGE-D2-expressing cells exhibited 
abnormal nuclear morphology (Figure 3-5, phase-contrast image and top right 
panel). It is not clear whether this change in nuclear structure represents 
apoptosis-induced nuclear fragmentation.  
 Next, using antibodies that we generated for MAGE-D2, we were able to 
examine the localization of the endogenous protein. U2OS cells were fixed and 
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immunofluorescence stained with MAGE-D2 (MD2-262) antibody. As observed 
with the ectopically expressed proteins, endogenous MAGE-D2 localized 
primarily to the nucleoli, followed by the nucleus (Figure 3-6). However, a small 
amount of cytoplasmic staining was also detected in a pattern reminiscent of 
mitochondria. To determine whether this indeed represented mitochondrial 
staining, we co-stained cells with MitoTracker™ dye and observed co-localization 
(Figure 3-6), suggesting that a portion of endogenous MAGE-D2 localizes to the 
mitochondria. Interestingly, the localization of endogenous MAGE-D2 appears 
quite heterogeneous, with some cells exhibiting primarily nucleolar and nuclear 
staining, while other cells have stronger staining in the mitochondria, and others 
have staining that appears diffuse throughout the nucleus and cytoplasm (Figure 
3-7). 
The ectopically expressed, tagged MAGE-D2 proteins did not appear to 
localize to the mitochondria, but it is not uncommon for protein tags to disrupt 
mitochondrial targeting. An epitope placed at the N-terminus of p32 or SUMI-1, 
for example, blocks mitochondrial import of these proteins (Figure 4-6E and data 
not shown). It is possible that the mitochondrial staining detected by the MAGE-
D2 antibody represents a nonspecific protein, but this is not likely, as the 
antibody appears highly specific to MAGE-D2—No other bands were observed 
on a whole-membrane western blot using the MD2-262 antibody (Figure 3-3, 
right panel). MAGE-D2 does not contain an obvious mitochondrial targeting 
signal; however, mitochondrial targeting is often  directed by a cryptic 
combination of N-terminal sequence features such as secondary structure, 
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enrichment of certain types of residues, number of acidic residues, 
hydrophobicity, and isoelectric point (Claros and Vincens, 1996). According to 
MitoProt II, a prediction program for mitochondrial localization that takes into 
account 47 sequence parameters affecting mitochondrial targeting, the 
probability that MAGE-D2 is exported to mitochondria is low (0.0452) (Claros and 
Vincens, 1996). It is possible, however, that the association of MAGE-D2 with 
mitochondria is based on interaction with another mitochondria-localized protein. 
This scenario seems plausible, as MAGE-D2 interacts with the mitochondrial 
protein p32. Immunogold-electron microscopy data shows that a portion of p32 
localizes to the mitochondrial outer membrane (data not shown), where it could 
interact with MAGE-D2 following translation of the protein in the cytoplasm.  
Altogether, based on detection of ectopic and endogenous MAGE-D2 with 
three different antibodies, it is clear that MAGE-D2 localizes to the nucleoli and 
nucleus, and immunofluorescence staining of endogenous MAGE-D2 also 
suggests that a subset of MAGE-D2 may localize to the mitochondria and to the 
cytoplasm.  These findings could be further examined with additional 
experiments such as subcellular fractionation. 
 
Exploring a Potential Role for MAGE-D2 in Regulating Apoptotic Cell Death 
 Because MAGE-D2 interacts with the pro-apoptotic protein p32, we 
examined whether MAGE-D2 might also regulate apoptosis. First, we 
overexpressed MAGE-D2 and examined the effect on cells with and without 
additional apoptotic stimuli.  U2OS cells were transfected with MAGE-D2-Flag 
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DNA or a control vector, and 24 hours later cells were treated with UV to induce 
apoptosis. After 18 hours, cells were examined. Ectopic expression of MAGE-D2-
Flag appeared to have little effect on cells in the absence of UV but appeared to 
sensitize cells to UV-induced cell death, as indicated by fewer of the MAGE-D2-
transfected cells surviving UV treatment (Figure 3-8). To obtain a quantitative 
measure of the effect of MAGE-D2 expression on cell death, flow cytometry 
analysis of cell death was performed. U2OS cells were treated as above except 
that 18 hours after UV treatment, cells were collected, fixed, and stained with 
propidium iodide for flow cytometry assessment of DNA content. Cells in the G1 
phase of the cell cycle have a diploid (2n) DNA content, while cells in G2 have 
duplicated their DNA in preparation for cell division and therefore contain a 
tetraploid (4n) quantity of DNA. Cells that are undergoing apoptosis contain DNA 
that has partially degraded; thus, any cells whose DNA content is less than that 
of the G1 peak (“sub-G1,” or sub-diploid) are considered to be apoptotic. MAGE-
D2 expression alone did not significantly increase the percentage of sub-G1 cells 
in the absence of apoptotic stimuli (2.2% of cells in sub-G1, compared to 1.4% 
for vector alone), but MAGE-D2 sensitized cells to UV-induced cell death (25% of 
cells in sub-G1 compared to 11% for vector alone) (Figure 3-9). These data 
suggest that, while MAGE-D2 expression alone is not sufficient to induce 
apoptosis in U2OS cells, MAGE-D2 might have an apoptosis-promoting function, 
sensitizing cells to apoptotic stimuli. Additional studies must be carried out to 
determine definitively whether MAGE-D2 regulates apoptotic cell death. 
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Summary and Discussion 
 MAGE-D2 is an uncharacterized MAGE (melanoma antigen) family protein 
that, unlike the majority of MAGE family members, is ubiquitously expressed in 
normal adult tissues. MAGE-D2 is a Type II MAGE protein, meaning that in 
addition to sharing the MAGE homology domain (MHD I) with all MAGE proteins, 
it also shares a MAGE homology domain II (MHD II) with a subset of MAGE 
proteins, including the MAGE-D subfamily. The physiological functions of MAGE 
proteins are mostly unknown, but roles have been reported in the regulation of 
cell survival, cell proliferation, ubiquitin ligase activity, and apoptosis (Barker and 
Salehi, 2002; Doyle et al., 2010). The closest homolog of MAGE-D2, MAGE-
D1/NRAGE, regulates apoptosis through several distinct mechanisms, but the 
functions of MAGE-D2 are unknown. In order to explore a potential function for 
MAGE-D2 in regulation of apoptosis, we generated several tools for its study, 
including tagged proteins for ectopic expression and antibodies for biochemical 
analyses of endogenous MAGE-D2 in cells.  
Using these tools combined with immunofluorescence imaging, we first 
examined the subcellular localization of MAGE-D2 and determined that it resides 
in the nucleus, nucleoli, and possibly mitochondria, and that its expression is 
heterogeneous among cells, with some cells harboring a greater proportion of 
MAGE-D2 in the nucleoli and the nucleus, and with other cells showing mostly 
mitochondrial staining. However, as the tagged, ectopically-expressed MAGE-D2 
proteins did not also localize to the mitochondria, additional studies are needed 
to determine whether the apparent mitochondrial localization could represent an 
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experimental artifact due to recognition of a nonspecific protein by the MAGE-D2 
antibody. One method for answering this question is through knockdown of 
MAGE-D2 with RNAi followed by immunofluorescence staining with MAGE-D2 
antibody to determine whether the mitochondrial signal disappears. If RNAi 
reduces the mitochondrial staining, we can conclude that the apparent 
mitochondrial localization is genuine. Another means to confirm the localization 
of MAGE-D2 is through subcellular fractionation, such as the differential 
detergent mechanism that was utilized in Chapter IV (Figure 4-7) to assess the 
localization of SUMI-1. 
The subcellular localization of a protein can provide clues to its function. 
Ectopic and endogenous MAGE-D2 were both observed to reside in the nucleus 
and nucleoli. The nucleus is a membrane-bound organelle containing the cell’s 
chromosomes. The primary functions that take place inside the nucleus are gene 
transcription and pre-mRNA processing. Nuclear proteins have widely varying 
roles such as regulation of gene expression, modulation of chromatin structure, 
sensing and repair of DNA damage, and cell cycle control. It is possible that 
MAGE-D2 might carry out one of these functions, such as responding to DNA 
damage and/or regulating transcription, in order to mediate apoptosis or another 
cellular process. Other MAGE proteins have been reported to regulate gene 
expression, many of them by modulating the transcriptional activity of the tumor 
suppressor p53 (Barker and Salehi, 2002). MAGE-D2 was also reported to 
interact with p53 in screen for novel p53 binding partners using a yeast p53-
dissociation assay (Papageorgio et al., 2007), although the function for this 
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interaction has not been determined. The nucleolus is a sub-nuclear body whose 
main functions are to carry out synthesis of ribosomal RNA (rRNA) and assembly 
of ribosomes—complexes consisting of proteins and RNA that translate proteins 
from mRNA sequences. Many proteins found in the nucleolus are components of 
the ribosomes themselves, and others regulate ribosomal biogenesis or rRNA 
synthesis, but a number of proteins in this compartment have no known ties to 
nucleolar functions. It has been proposed that the nucleolus might act as a 
storage area for proteins, keeping them inactive until they are required elsewhere 
in the cell (Pederson and Tsai, 2009). Immunofluorescence staining of 
endogenous MAGE-D2 suggests that it may also reside in the mitochondria. 
Inside this organelle, ATP is produced by oxidative phosphorylation, providing 
most of the energy supply for the cell. Mitochondria also play an important role in 
the intrinsic apoptotic pathway. During apoptosis, the mitochondrial outer 
membrane is permeabilized, releasing cytochrome c and other contents of the 
mitochondrial intermembrane space, leading to Caspase activation and 
execution of apoptosis (Chipuk et al., 2010). Thus, it is possible that MAGE-D2 
mediates apoptosis through its association with the mitochondria.  
We examined a role for MAGE-D2 in regulating apoptosis, and we found 
that overexpression of MAGE-D2-Flag sensitized cells to UV-induce apoptosis. 
While this preliminary result suggests that MAGE-D2 may have an apoptosis-
promoting function, it is possible that this result is an artifact of protein 
overexpression. In order to determine whether MAGE-D2 has a physiologically-
relevant role in apoptosis regulation, additional studies are required. For 
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example, it can be determined whether knockdown of MAGE-D2, such as with 
siRNA, affects apoptosis. One complication is that extensive redundancy is 
thought to exist among MAGE family members, so knockdown of one MAGE 
protein may be compensated for by another. It may be necessary to inhibit more 
than one MAGE protein (e.g. MAGE-D2 and MAGE-D1) to see an effect. 
Mechanistic studies can also help determine whether MAGE-D2 has a bona-fide 
role in regulating apoptosis. In addition, we have not demonstrated that 
overexpression of MAGE-D2 increases apoptosis, per se, rather than another 
form of cell death. While quantification of apoptosis by assessing the percentage 
of cells with sub-G1 content is highly precise for cells that are not actively cycling, 
such as thymocytes, this method is not flawless for analysis of cycling cells, as it 
does not discriminate between apoptotic cells, fragmented cells, and other 
debris—a clear peak representing apoptotic cells cannot be observed in cycling 
cells. Other assays must be carried out to examine other markers of apoptosis, 
such as western blotting for PARP cleavage or Caspase-3 activation.  
Interestingly, we observed several phenomena suggesting that MAGE-D2 
might regulate, or be regulated by, the cell cycle and/or cell proliferation. First, 
the subcellular localization of MAGE-D2 appears heterogeneous from cell to cell, 
and it is possible that its location may change during cell cycle progression. To 
test this, the cell cycle could be synchronized with cycloheximide, and cells could 
be fixed at different time points for immunofluorescence analysis of MAGE-D2 
localization. Second, in confluent U2OS cells, MAGE-D2 expression seems to 
disappear in patches of cells (Figure 3-10). In U2OS cells fixed for 
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immunofluorescence, confluent regions contained patches of cells expressing 
little to no endogenous MAGE-D2. It would be interesting to determine whether 
expression of MAGE-D2 is linked to cell proliferation and/or cell cycle control.  
 
Materials and Methods 
 
Cell Culture, transfection, and apoptotic treatments. U2OS cells were 
obtained from ATCC and cultured in a 37°C incubator with 5% CO2 in DMEM 
supplemented with 10% FBS, 100 U/ml penicillin, and 100 g/ml streptomycin. 
DNA transfections were carried out with Effectene® (Qiagen) according to the 
manufacturer’s instructions. Apoptosis treatments included UVC radiation 
(dosage as indicated) using a Stratalinker® UV Crosslinker (Stratagene) and 
cisplatin (10 µg/ml). 
 
SDS-PAGE and western blotting. Cells were lysed in 0.1% NP-40 lysis buffer, 
and samples were resolved by SDS-PAGE using a 12.5% or 15% polyacrylamide 
gel and transferred onto a 0.2 µM nitrocellulose membrane. Membranes were 
blocked for a minimum of 30 minutes in phosphate-buffered saline with 0.1% 
Tween-20 (PBST) and 5% nonfat dried milk. Membranes were incubated for 2 
hours to overnight in primary antibody, incubated for 1-2 hours in secondary 
HRP-conjugated antibody, and exposed with Supersignal West Pico (Pierce).  
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DNA plasmids. N-terminally Myc tagged and C-terminally Flag-tagged MAGE-
D2 were cloned into a pcDNA3.1 vector (Invitrogen). MAGE-D2 was cloned into a 
pEGFP-N1 vector (Clontech) to generate a MAGE-D2-EGFP fusion protein. All 
plasmids were confirmed by restriction digest and DNA sequencing.  
 
Generation of antibodies. Rabbit anti-MAGE-D2 antibodies were produced by 
immunizing rabbits (performed by PRF&L, Canadensis, PA) with KLH-conjugated 
peptide antigens corresponding to amino acids 180-194 (MD2-180) and 262-278 
(MD2-262) of MAGE-D2. Sera were affinity purified, and antibody specificity was 
tested by western blotting (Figure 3-2).  
 
Flow cytometry analysis. Cells were trypsinized, washed in PBS, and fixed in 
cold 70% ethanol. Cells were treated with RNAse A and stained with propidium 
iodide. Cells were analyzed using a FACSCalibur flow cytometer (BD 
Biosciences) at the UNC Flow Cytometry Core Facility, and data were analyzed 
with Dako software.  
 
Immunofluorescence imaging. Cells were fixed in 4% paraformaldehyde for 10 
minutes at room temperature and permeabilized in 0.2% Triton X-100 for 5 
minutes at 4°C. Fixed and permeabilized cells were blocked for 30 minutes in 
0.5% BSA blocking buffer in PBS, incubated in primary antibody overnight at 4°C 
with rocking, and incubated with secondary antibodies (anti-mouse or –rabbit 
rhodamine red) for 30 minutes at room temperature with rocking.  Nuclei were 
51 
stained with DAPI (diamidino-2-phenylindole), and mitochondria were visualized 
with MitoTracker™ Red (Invitrogen) where indicated. Cells were mounted in 
fluorescence mounting medium (Dako) and analyzed using an Olympus IX81 
inverted microscope combined with a SPOT™ digital microscope camera and 
imaging software (SPOT™ Imaging Solutions).   
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Figure 3-1.  Domain structure for MAGE-D2. 
MAGE-D2 contains two known functional domains. MHD I (MAGE homology 
domain 1), which extends from amino acids (aa) 279 to 476, is shared by all 
MAGE family proteins. MHD II (Mage homology domain II), extending from aa 
54-252, is shared by Type II MAGE proteins, including all members of the 
MAGE-D subfamily. The functions for these domains are not known. 
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Figure 3-2.  Antibody design for MAGE-D2. 
A) MAGE-D2 protein sequence showing approximate location of peptide antigens 
selected for production of MAGE-D2 rabbit polyclonal antibodies Red triangles 
indicate the approximate positions of the selected peptides relative to MAGE 
homology domains (MHD) I and II. 
B) The MAGE-D2 protein sequence with the two selected peptide antigens 
(MD2-180 and MD2-262) shown in red and underlined. 
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Figure 3-3. MAGE-D2 antibody effectiveness and specificity. 
Whole-membrane western blots showing specificity and effectiveness for 
antibodies targeting two different regions of MAGE-D2 (MD2-180, aa 180-194; 
MD2-262, aa 262-276). Endogenous MAGE-D2 and Flag-tagged MAGE-D2 are 
detected by both MAGE-D2 antibodies 
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Figure 3-4. Ectopically-expressed tagged MAGE-D2 localizes to nuclei and 
nucleoli. 
Immunofluorescence staining shows MAGE-D2 localization primarily in the cell’s nucleus 
and nucleoli. U2OS cells were transfected with indicated plasmids and fixed after 24 h 
for immunofluorescence staining with Flag or Myc antibodies. MAGE-D2 that is fused 
with an N-terminal Myc3 tag (top left panel) can be seen exclusively in the nucleoli and 
nucleus. C-terminally-tagged MAGE-D2-FLAG can be seen primarily in the nucleoli and 
nucleus, with faint staining also detectable in the cytoplasm. Corresponding phase-
contrast images are shown below.   
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Figure 3-5. Expression of EGFP-tagged MAGE-D2 is toxic to cells and 
disrupts nuclear and nucleolar morphology. 
A) Live-cell fluorescence imaging of U2OS cells transfected with N-terminally-
EGFP-tagged MAGE-D2 shows that expression of this construct is toxic to cells, 
with many transfected cells dying (observed as shrunken, white floating cells in 
phase-contrast image).  
B) Effect of EGFP-MAGE-D2 on cell morphology shown in fixed cells. U2OS cells 
were transfected with EGFP-MAGE-D2, fixed after 18 h, and visualized by 
fluorescence microscopy. Many nuclei of transfected cells appear fragmented, 
and nucleoli appear abnormal (see close-up in panels on right).  
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Figure 3-6. Endogenous MAGE-D2 localizes to the nucleoli, nuclei, and 
mitochondria. 
Untransfected U2OS cells were immunofluorescence stained for MAGE-D2 
(MD2-262 antibody). Endogenous MAGE-D2 is observed in the nucleoli and 
nucleus. MAGE-D2 staining was also observed at the mitochondria, as indicated 
by colocalization with the mitochondrial marker MitoTracker. 
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Figure 3-7. Localization of endogenous MAGE-D2 is heterogeneous. 
The localization of MAGE-D2 varies significantly from cell to cell. Untreated 
U2OS cells were immunofluorescence-stained for endogenous MAGE-D2 with 
antibody MD2-262. Some cells exhibit primarily mitochondrial staining (white 
arrow), some cells show primarily nucleolar and nuclear staining (blue arrow), 
and some cells exhibit diffuse cytoplasmic and nuclear staining (yellow arrow). 
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Figure 3-8. Overexpression of MAGE-D2 sensitizes cells to UV-induced cell 
death. 
U2OS cells were transfected with pcDNA3 vector alone or pcDNA3-MAGE-D2-
Flag3, as indicated. After 24 hours, cells were either left untreated (None) or 
treated with 6 mJ/cm2 UV for 18 hours. Apoptotic cells appear shrunken, 
rounded, and white, and eventually detach from the plate. Many of the cells 
treated with both MAGE-D2-Flag and UV (bottom right panel) have detached 
from the substrate and appear in clusters. 
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Figure 3-9. Flow cytometry analysis of effect of MAGE-D2 expression on 
UV-induced apoptosis. 
A) Flow-cytometry analysis shows that ectopic expression of MAGE-D2 
sensitizes cells to UV-induced cell death. U2OS cells were transfected with 
MAGED2-Flag DNA, treated 24 h later cells with UV (6 mJ/cm2) where indicated 
to induce apoptosis, and were fixed 18 h later in ethanol, stained with propidium 
iodide, and analyzed by flow cytometry for DNA content.  
B) Graphical representation of data from (A).  
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Figure 3-10. Endogenous MAGE-D2 expression is absent in patches of 
confluent cells.  
In confluent U2OS cells immunofluorescence-stained for endogenous MAGE-D2 
with MD2-262 antibody, patches of cells are observed with greatly-reduced 
MAGE-D2 expression. Note that the phase-contrast image on the right shows 
that the entire field is filled with cells, yet areas are observed in the 
immunofluorescence image that lack MAGE-D2 expression.  
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CHAPTER IV 
 
 
SUMI-1 IS A NOVEL REGULATOR OF MITOCHONDRIAL  
FISSION-FUSION DYNAMICS AND BAX-MEDIATED APOPTOSIS1 
 
Introduction 
A critical control point during apoptosis is mitochondrial outer membrane 
permeabilization (MOMP), during which mitochondrial contents such as 
cytochrome c are released in order to initiate apoptosis. As MOMP is often the 
“point of no return” during apoptosis, much research is currently devoted to 
understanding this process. Our knowledge of MOMP remains incomplete but 
can be enhanced by identification of novel proteins involved in its regulation. 
Here, we characterize a small protein, “SUMI-1,” that resides at the mitochondrial 
outer membrane and inhibits apoptosis. We show that early in apoptosis, SUMI-1 
translocates from the mitochondria, promoting BAX oligomerization, MOMP, and 
cytochrome c release. We also show that SUMI-1 controls mitochondrial 
fusion/fission dynamics, providing a mechanism for its regulation of apoptosis. 
Furthermore, SUMI-1 is overexpressed in many cancers, and knockdown of 
SUMI-1 sensitizes cancer cell lines to chemotherapeutic drugs, suggesting that 
SUMI-1 is a potential target for chemosensitizing therapeutics.  
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Background 
Apoptosis, or programmed cell death, is a critical process during 
vertebrate development and is abnormally regulated in a diverse array of 
diseases. Apoptosis can occur through two pathways—receptor-mediated 
(extrinsic) apoptosis, and mitochondria-mediated (intrinsic) apoptosis. The 
extrinsic pathway is activated by interaction of extracellular ligands with death 
receptors, while the intrinsic pathway is triggered by intracellular stresses such 
as DNA damage and is modulated by the cell’s mitochondria. Both pathways 
converge upon activation of cysteine proteases (Caspases), which cleave 
downstream substrates to induce the physiological and morphological changes 
associated with apoptosis such as membrane blebbing, DNA fragmentation, and 
cell shrinkage.  
The intrinsic pathway is regulated largely by pro- and anti-apoptotic BCL-2 
family proteins, which together dictate whether a cell undergoes mitochondrial 
outer membrane permeabilization (MOMP). During MOMP, which is often the 
point of no return for cells undergoing apoptosis, pro-apoptotic BCL-2 effector 
proteins BAX and/or BAK oligomerize on the mitochondrial outer membrane, 
releasing cytochrome c and other mitochondrial intermembrane space contents 
into the cytoplasm to induce apoptosis. The decision to undergo MOMP is also 
influenced by non-BCL-2 proteins and by mitochondria themselves. Mitochondrial 
fission-fusion dynamics have recently emerged as a means by which apoptosis is 
modulated. Mitochondria are dynamic, continually dividing and merging with one 
another. During apoptosis, mitochondria become fragmented prior to MOMP, due 
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to an increase in fission and/or a decrease in fusion. Overexpression of fusion-
promoting proteins MFN1 or MFN2 protects cells from apoptosis (Brooks et al., 
2011), while inhibition of fission-mediating DRP1 partially inhibits mitochondrial 
fragmentation while delaying MOMP and apoptosis (Brooks et al., 2011). 
Recently, it was shown that DRP1-induced mitochondrial fragmentation promotes 
apoptosis by stimulating BAX oligomerization (Montessuit et al., 2010). Despite 
advances that have been made in our understanding of MOMP, much remains 
unknown about the mechanisms leading to BAX activation and oligomerization, 
especially the roles that mitochondria and their associated proteins play in this 
process. Identification of novel proteins that regulate MOMP can significantly aid 
in our understanding of this process.  
Here, we characterize a small, mitochondria-localized protein that we call 
SUMI-1 for survival-promoting mitochondrial protein 1 (also known as CHCHD2 
for coiled-coil-helix coiled-coil helix domain-containing 2) as a novel regulator of 
mitochondrial dynamics and mitochondria-mediated apoptosis. We initially 
identified SUMI-1 as an interacting partner for the pro-apoptotic protein 
p32/C1QBP; however, this study focuses on characterizing SUMI-1’s apoptosis-
regulating function, while subsequent studies will be devoted to its interaction 
with p32. SUMI-1 was recently detected in screens for proteins regulating cellular 
metabolism and migration (Baughman et al., 2009; Seo et al., 2010), but its 
functions have not been well-characterized. Here, we report that SUMI-1 acts as 
a guardian of mitochondrial membrane integrity by inhibiting BAX-induced 
mitochondrial outer membrane permeabilization. We also show that SUMI-1 
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regulates mitochondrial fusion in order to maintain a balance between fusion and 
fission, providing a mechanism for SUMI-1’s regulation of BAX and MOMP. 
Furthermore, most of these experiments were carried out in intact cells using 
endogenous rather than overexpressed proteins, and our results are therefore 
likely to be physiologically relevant. Finally, we observed that SUMI-1 expression 
is upregulated in cancer cell lines, and data obtained from Oncomine™ 
demonstrates that SUMI-1 is indeed overexpressed in multiple cancers, 
consistent with SUMI-1’s anti-apoptotic function. This study identifies a novel 
regulator of apoptosis, sheds light on previously-unexplained mechanisms 
governing mitochondrial dynamics, MOMP, and BAX activation in regulating 
apoptotic cell death, and provides a potential therapeutic target for 
chemosensitization in cancer treatment.  
 
SUMI-1 is a Highly-Conserved CHCH-Domain-Containing Protein 
The CHCHD2 gene encoding SUMI-1 spans 4921 base pairs, contains 4 
exons, and is located on chromosome 7p11.2, a region amplified in 
glioblastomas (Arslantas et al., 2004). The protein encoded by this gene is 
expressed broadly in adult tissues (Shmueli et al., 2003) and is a relatively small 
protein, comprised of 151 amino acids. SUMI-1 is relatively well-conserved, with 
87% amino acid identify in mice, and is conserved through yeast (Table 4-1, 
Figure 4-1). SUMI-1 contains three functional domains: a putative mitochondrial 
targeting signal at the N-terminus (Claros and Vincens, 1996), a predicted 
transmembrane domain (TMBASE), and a C-terminal CHCH (coiled-coil helix-
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coiled-coil helix) domain. SUMI-1 also contains a consensus sequence for import 
into the mitochondrial intermembrane space (ITS) mediated by another CHCH-
domain-containing protein, Mia40 (Figure 4-2).  
The CHCH domain is characterized primarily by four cysteine residues 
spaced exactly 10 amino acids apart (a C-X9-C motif) (Schultz et al., 1998).  
Pairs of cysteines in this domain typically form covalent disulfide bonds, eliciting 
changes in tertiary protein structure or facilitating oligomerization and/or 
interactions with other CHCH domain-containing proteins (Arnesano et al., 2005). 
Analysis of the SUMI-1 sequence with an intramolecular disulfide connectivity 
prediction program, DiANNA 1.1, predicts that a bond may form between 
cysteines 1-3 and another bond between cysteines 2-4 in the CHCH domain to 
create a loop structure at the C-terminus (Figure 4-3) (Ferre and Clote, 2005a, 
b). 
The function of the CHCH domain is not well understood, and the few 
characterized proteins that carry this domain have diverse functions; these 
proteins include Cox12, Cox17, Cox19, Cox23, Mia40/Tim40, C2360, and 
MRP10. The yeast protein Cox12 is part of the COX (cytochrome c oxidase) 
complex, which is the final enzyme in the respiratory electron transport chain 
(LaMarche et al., 1992). Cox17, Cox19, and Cox23 play roles in assembly of the 
COX complex; specifically, they are thought to feed copper ions into the complex 
during assembly, and their CHCH domains may be important for copper ion 
binding (Arnesano et al., 2005; Barros et al., 2004; Nobrega et al., 2002). Of 
these proteins, Cox17 has been studied the most extensively, and its function in 
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COX assembly has recently been shown to be mediated by its interaction with 
SCO-1 (Banci et al., 2008a). Mia40/Tim40 assists in transporting proteins into the 
mitochondrial intermembrane space by forming temporary disulfide bonds with 
cysteine-containing proteins as they are imported (Chacinska et al., 2004; 
Hofmann et al., 2005; Sideris et al., 2009). C2360 is expressed only in human 
proliferative cytotrophoblasts and not in adult tissues; its function is unknown 
(Westerman et al., 2004). Finally, the yeast protein MRP10 is a component of the 
mitochondrial ribosomal 37S subunit, which mediates translation of proteins (Jin 
et al., 1997). The function of the CHCH domain has been studied most 
extensively in Cox17, where the domain was shown to change configuration 
based on oxidative-reductive status, and is thought to regulate homo-
oligomerization (Arnesano et al., 2005). The CHCH domain in SUMI-1 is well-
conserved across species: The four cysteines comprising the domain are present 
in 8 of the 9 orthologs shown in Figure 4-1.  
 
Generation of Antibodies for Study of Endogenous SUMI-1 
At the onset of our study, no antibodies were available for biochemical 
analyses of endogenous SUMI-1. Thus, we designed two rabbit polyclonal 
antibodies as described in Chapter III in order to study endogenous, untagged 
SUMI-1, avoiding potential artifacts introduced by protein tags and 
overexpression. Antigen options were limited because SUMI-1 is a small protein 
(151 amino acids) and consists of a predicted mitochondrial targeting signal at 
the N-terminus, a putative transmembrane domain in the center of the protein, 
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and CHCH domain comprised of four cysteines spaced 10 amino acids apart at 
the C-terminus. These features made the majority of the sequence unsuitable or 
undesirable because the mitochondrial targeting region could potentially be 
cleaved off the protein upon mitochondrial translocation, the transmembrane 
region is hydrophobic (meaning it is not likely to be exposed at the protein 
surface), and the closely-spaced cysteines in the CHCH domain precluded any 
antigens longer than 10 amino acids due to the need to have either zero or one 
terminally-located cysteine and no internal cysteines in the antigen sequence. 
The regions selected were SU-94 (amino acids 94-108; RPDITYQEPQGTQPA), 
located adjacent to the central transmembrane domain, and SU-124 (amino 
acids 124-133; CAQNQGDIKL), located within the CHCH domain (Figure 4-4). 
The second antigen was shorter than desired (10 amino acids) in order to ensure 
that no internal cysteines were present in the sequence. The peptides were used 
to immunize rabbits, and the resulting serum containing polyclonal antibodies 
was affinity-purified as described in Chapter III. The purified antibodies were then 
tested by western blotting and immunofluorescence for effectiveness and 
specificity. The antibody generated with the SU-94 antigen is highly specific to 
SUMI-1 and can be used for western blotting, immunofluorescence, and co-
immunoprecipitation (Figures 4-5 and 2-5).  
 
SUMI-1 Localizes to the Mitochondria 
SUMI-1 is predicted by MitoProt to localize to mitochondria, with the first 
51 amino acids serving as a putative mitochondrial targeting sequence (Claros 
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and Vincens, 1996).  To determine whether SUMI-1 indeed localizes to the 
mitochondria, we examined its subcellular localization by immunofluorescence. 
We transfected U2OS cells with plasmids expressing C-terminal Flag-tagged 
SUMI-1, fixed the cells after 24 hours, and carried out immunofluorescence 
staining for Flag. SUMI-1-Flag localized primarily to mitochondria, as indicated by 
co-staining with MitoTracker™ dye (Figure 4-6A). 
 Next, we examined the localization of endogenous SUMI-1 by 
immunofluorescence staining with SUMI-1 antibody in unstressed U2OS cells. 
Like SUMI-1-Flag, endogenous SUMI-1 was observed to localize primarily to 
mitochondria, as indicated by co-staining for the mitochondrial marker 
cytochrome c (Figure 4-6B). This localization was also observed in HeLa cells 
(Figure 4-6C) and mouse embryo fibroblasts (MEFs) (Figure 4-6D). The 
mitochondrial localization of SUMI-1 was further confirmed by a differential 
detergent subcellular fractionation method, with SUMI-1 appearing in the 
mitochondria-enriched heavy membrane fraction, consistent with our 
immunofluorescence results (Figure 4-7). To examine the submitochondrial 
localization of endogenous SUMI-1, we carried out immunogold staining in which 
gold beads were conjugated to SUMI-1 antibody and applied to formaldehyde-
fixed U2OS cells before or after paraffin embedding. Using a pre-embedding 
staining method, endogenous SUMI-1 could be observed by electron microscopy 
(EM) around the perimeter of the mitochondria, suggesting that SUMI-1 resides 
at the mitochondrial outer membrane (Figure 4-8).  Using a pre-embedding 
staining method, SUMI-1 was similarly detected at the mitochondrial outer 
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membrane and could also be observed inside the mitochondria, although the 
sub-mitochondrial localization (i.e. matrix, inner membrane, or intermembrane 
space) was not clear (Figure 4-8). Thus, SUMI-1 appears to reside both inside 
the mitochondria and at the outer mitochondrial membrane. SUMI-1 contains a 
consensus ITS (intermembrane targeting sequence) that directs Mia40-mediated 
import of proteins into the mitochondrial intermembrane space. It is possible that 
upon import, a subset of SUMI-1 is retained in the mitochondria (either in the 
intermembrane space or embedded in the inner membrane) while another subset 
becomes anchored via the transmembrane domain into the mitochondrial outer 
membrane. 
 Another study that identified SUMI-1 in a screen for novel mediators of cell 
migration also examined the subcellular localization of SUMI-1 and reported that 
SUMI-1 resides in the cytoplasm. However, the authors examined only the sub-
cellular localization of N-terminally tagged protein, and an N-terminal tag often 
disrupts mitochondrial localization in proteins containing an N-terminal MTS. We 
also examined the localization of N-terminally tagged Myc-SUMI-1 by 
immunofluorescence, and as expected, the mitochondrial localization was lost, 
with the N-terminally-tagged protein appearing primarily in the cytoplasm and 
nucleus (Figure 4-6E). 
 Thus, based on immunofluorescence imaging of C-terminally tagged and 
endogenous SUMI-1, subcellular fractionation, and immunogold-EM imaging, we 
conclude that in healthy, unstressed cells, SUMI-1 resides primarily in the 
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mitochondria, with a subset of SUMI-1 located within the mitochondria and 
another portion associated with the mitochondrial outer membrane.  
 
SUMI-1 Inhibits Apoptotic Cell Death 
We next sought to determine whether SUMI-1 plays a role in regulating 
apoptotic cell death. We first analyzed whether SUMI-1 knockdown affects 
apoptosis, using two different siRNA duplexes targeting different regions of 
SUMI-1 mRNA. We treated cells with nonspecific control siRNA (NS) or two 
different SUMI-1 siRNA species as indicated for 48 hours and subjected cells to 
various apoptosis-inducing treatments to determine whether a reduced SUMI-1 
level could affect response to the treatments. SUMI-1 knockdown alone caused 
little to no increase in cell death in the absence of apoptotic stimuli (average 95% 
of control), SUMI-1 knockdown sensitized cells to apoptosis as measured by 
quantification of cells surviving treatment with cisplatin (27% of control), UV 
radiation (64% of control), doxorubicin (54% of control), and staurosporine (69% 
of control) (Figure 4-9A). Additionally, we tested the effect of SUMI-1 knockdown 
in HeLa cells treated with UV radiation and cisplatin. Consistent with the U2OS 
data, SUMI-1 siRNA did not significantly affect apoptosis in the absence of 
apoptotic stimuli (92% of control) but sensitized HeLa cells to cell death induced 
by cisplatin (34% of control) and UV (43% of control) (Figure 4-9B). The pattern 
we observed here was similar to that observed with knockdown of known anti-
apoptotic proteins such as BCL-2, BCL-xL, and MCL-1; inhibition of these 
proteins alone does not usually cause cell death, but sensitizes cells to apoptotic 
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stimuli (Chipuk et al., 2010). To confirm whether the decrease in cell number 
resulting from these treatments was indeed due to apoptosis, we carried out 
western blotting to examine the level of cleaved poly (ADP-ribose) polymerase 
(PARP) and Caspase-3, both indicators of apoptosis (Simbulan-Rosenthal et al., 
1998). Cells treated with UV exhibited PARP and Caspase-3 cleavage, and this 
was augmented by pre-treatment with SUMI-1 siRNA (Figure 4-10). In addition, 
apoptosis-associated morphological changes (cell shrinkage, detachment, 
rounding, and membrane blebbing) were observed in cells treated with apoptotic 
agents, and these features were enhanced upon SUMI-1 knockdown (example 
shown in Figure 4-11). U2OS cells were treated with the indicated siRNA for 48 
hours followed by UV radiation (6 mJ/cm2) where indicated, and images were 
taken at 10x magnification. Membrane blebbing can be observed clearly in a 
higher-magnification (40x) image of U2OS cells treated with SUMI-1 siRNA and 
UV (Figure 4-11). Together, these data show that SUMI-1 knockdown sensitizes 
cells to apoptotic cell death, implicating SUMI-1 as a negative regulator of 
apoptosis.  
 We then tested whether overexpression of SUMI-1 could protect cells from 
apoptosis. U2OS cells were treated with adenovirus expressing either untagged 
SUMI-1 (Ad-SUMI-1) or GFP as a negative control (Ad-Ctl), and sensitivity to 
apoptosis was assessed both with and without apoptosis-inducing UV treatment. 
Overexpression of SUMI-1 had no significant effect on unstressed cells, with 
similar survival between cells treated with control adenovirus (normalized to 
100%) and those treated with SUMI-1 adenovirus (106% of control), whereas 
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SUMI-1 overexpression protected UV-treated cells from apoptosis (89% survival 
compared to 51% for control) (Figure 4-12A). SUMI-1 overexpression also 
reduced PARP cleavage during UV-induced apoptosis as determined by western 
blotting (Figure 4-12B). Together with the SUMI-1 knockdown experiments, these 
data strongly suggest that SUMI-1 is an inhibitor of apoptosis.  
 
SUMI-1 Translocates From Mitochondria Prior to Cytochrome c 
We next sought to identify the mechanism by which SUMI-1 regulates 
apoptosis. We had observed by immunofluorescence staining that endogenous 
SUMI-1 translocates from the mitochondria during apoptosis (Figure 4-13A). We 
co-stained cells for cytochrome c, which is itself released from mitochondria at an 
early stage during apoptosis. Interestingly, a subset of cells was observed in 
which SUMI-1 had translocated yet cytochrome c was still retained in the 
mitochondria (Figures 4-13B and 4-14), while no cells were observed to contain 
both released cytochrome c and mitochondrial SUMI-1. Thus, it appeared that 
SUMI-1 may translocate from the mitochondria prior to cytochrome c. To further 
test this, we examined cytochrome c and SUMI-1 localization over a time course 
in UV-treated U2OS cells and quantified the percentage of cells with released 
SUMI-1 at each time point, and the percentage of cells with released cytochrome 
c. Before administering UV irradiation, cells were pretreated with the pan-
Caspase inhibitor Q-VD-OPh (abbreviated QVD) to prevent cell death 
downstream of cytochrome c release, thereby preserving cells with released 
cytochrome c and allowing them to be visualized. Cells were treated with UV (25 
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mJ/cm2) and fixed for immunofluorescence staining at the indicated time points. 
At each time point, we observed a greater percentage of cells with SUMI-1 
release than with cytochrome c release, indicating that SUMI-1 translocates from 
the mitochondria prior to cytochrome c. Four hours post-UV, 12% of cells had 
released SUMI-1, while 7.6% had released cytochrome c; eight hours post-UV, 
40% and 23% of cells had released SUMI-1 or cytochrome c, respectively; and 
16 hours post-UV, 87% and 78% of cells had released SUMI-1 or cytochrome c, 
respectively (Figure 4-14B). These data indicate that SUMI-1 translocates from 
the mitochondria prior to cytochrome c. 
 
SUMI-1 Regulates Mitochondrial Outer Membrane Permeabilization (MOMP) 
and BAX Activation 
Our data show that SUMI-1 translocates from the mitochondria at an 
earlier time point than cytochrome c. Because cytochrome c release is a 
standard readout for MOMP (Arnoult, 2008), these data imply that SUMI-1 
translocates from the mitochondria prior to the onset of mitochondrial 
permeabilization. Therefore, we hypothesized that SUMI-1 may regulate 
MOMP—That is, SUMI-1 may protect healthy cells from apoptosis by inhibiting 
MOMP, and during apoptosis, SUMI-1 may translocate from the mitochondria, 
releasing this inhibition and allowing MOMP to proceed. In this case, inhibition of 
SUMI-1 by siRNA would be expected to promote MOMP. To evaluate this, we 
treated cells with either nonspecific or SUMI-1 siRNA for 48 hours, induced 
apoptosis with UV and performed immunofluorescence to visualize cytochrome c 
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release. Cells in which cytochrome c was released (staining appeared diffuse 
throughout the cell) were quantified. SUMI-1 knockdown significantly increased 
the kinetics with which cytochrome c was released, with a greater percentage of 
cells observed with released cytochrome c in si-SUMI-1-treated cells compared 
to si-NS-treated cells at 1 hour (3.9% and 1.2%, respectively),  2 hours (14% and 
5%, respectively), and 4 hours post-UV (35% and 7.5%, respectively) (Figure 4-
15), indicating that endogenous SUMI-1 inhibits MOMP.  
 We next examined potential mechanisms by which SUMI-1 might regulate 
MOMP. While the exact mechanisms governing MOMP are not entirely clear, 
MOMP is known to occur when BAX and/or BAK—two pro-apoptotic BCL-2 
family proteins—oligomerize on the mitochondrial outer membrane (Chipuk et al., 
2010). As BAX is one of the primary inducers of MOMP, we sought to determine 
whether SUMI-1 might regulate this protein. BAX continually cycles between the 
mitochondria and cytosol (Edlich et al., 2011). During apoptosis, BAX 
accumulates at the mitochondria, becomes activated, and forms oligomers on the 
mitochondrial outer membrane, inducing membrane permeabilization (Edlich et 
al., 2011; Wolter et al., 1997). Active BAX can be detected by 
immunofluorescence with BAX 6A7 antibody, which recognizes an N-terminal 
epitope that is hidden in the inactive protein but is exposed upon conformational 
changes during activation of BAX. Generally, positive staining with BAX 6A7 
indicates the presence of BAX that is both activated and oligomerized in clusters 
on the mitochondrial outer membrane. 
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To determine whether SUMI-1 inhibits BAX activation, we treated cells 
with SUMI-1 siRNA for 48 hours, induced apoptosis with UV, and examined BAX 
activation by immunofluorescence staining with BAX 6A7 antibody. Cells were 
pre-treated with QVD to inhibit apoptotic events downstream of cytochrome c 
release, preserving cells with activated BAX. Consistent with the experiments 
examining sensitivity to apoptosis and cytochrome c release, SUMI-1 knockdown 
alone did not induce BAX activation (Figure 4-16A, top two panels), but greatly 
increased BAX activation in UV-treated cells, as indicated by a stronger signal 
from BAX 6A7 antibody (Figure 4-16A, lower panels). We also noted that in 
U2OS and HeLa cells induced to undergo apoptosis with UV radiation, BAX 
activation was observed only in cells with released SUMI-1, with no active BAX 
observed in cells retaining mitochondrial SUMI-1 (Figure 4-16B). Thus, BAX 
activation/oligomerization correlated with SUMI-1 translocation in cells 
undergoing apoptosis. To examine BAX oligomerization by another method, 
purified mitochondria were treated with trypsin, which easily degrades BAX 
monomers but not oligomers (Lucken-Ardjomande et al., 2008). The trypsin-
treated mitochondria were lysed and resolved by SDS-PAGE and blotted for 
BAX. Any resulting signal detected by BAX antibody represents trypsin-resistant, 
oligomerized BAX (designated as TR-Bax). SUMI-1 knockdown augmented UV-
induced BAX oligomerization (Figure 4-17), consistent with the 
immunofluorescence data using BAX 6A7 antibody.  Together, these data 
suggest that SUMI-1 regulates MOMP during apoptosis by suppressing BAX 
activation.  
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SUMI-1 Does Not Regulate BCL-xL Deamidation 
 We next examined potential mechanisms by which SUMI-1 could regulate 
BAX activation. During apoptosis, activation and oligomerization of BAX are 
mediated in part by pro- and anti-apoptotic BCL-2 family members, as described 
in Chapter I. Thus, we carried out co-immunoprecipitation experiments to 
determine whether SUMI-1 interacts with any BCL-2 family proteins during 
apoptosis, including BAX itself. U2OS cells were lysed in 0.1% NP-40 lysis buffer 
and immunoprecipitated with SUMI-1 antibody or an isotype (IgG) antibody as a 
negative control. No interactions were detected between SUMI-1 and BCL-2 or 
BIM (Figure 4-18A, left panel). Other BCL-2 family proteins were also blotted for, 
including BAX and BAK, but no signal was observed in the loading controls (data 
not shown). BAX and BAK can be artificially induced to oligomerize in lysates 
containing NP-40 detergent and may not be detected at the expected size by 
SDS-PAGE and western blotting. To avoid this issue, cells can be lysed by 
alternate means such as with CHAPS lysis buffer. Thus, a co-IP looking for an 
interaction between SUMI-1 and BAX was repeated using CHAPS buffer. Here, 
Bax could be observed in the loading samples, but was not found to co-
immunoprecipitate with SUMI-1 (data not shown).  
An apparent interaction was detected between SUMI-1 and a pro-survival 
BCL-2 family protein, BCL-xL (Figure 4-18A, right panel).  To ensure that the 
binding was not due to nonspecific interaction between BCL-xL and the SUMI-1 
antibody, the experiment was repeated using cells stably-expressing SUMI-1 
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shRNA as a more stringent control, and two different SUMI-1 antibodies were 
utilized for the IP. Following incubation with each antibody, an interaction was 
observed between BCL-xL and SUMI-1. In sh-SUMI-1-expressing cells, less 
SUMI-1 was immunoprecipitated, and a corresponding decrease was observed 
in the BCL-xL band (Figure 4-18B).  
The bands that were detected by the BCL-xL antibody migrated slightly 
higher (~34  and 37 kD) than the predicted molecular weight (26 kD) for BCL-xL, 
and SUMI-1 interacted only with the 34 kD band. BCL-xL is reported to be 
modified by deamidation during apoptosis, causing a change in conformation and 
an associated upward shift in migration on SDS-PAGE (Deverman et al., 2002). 
Deamidation is a process whereby specific asparagine residues are converted, 
either enzymatically or non-enzymatically, to aspartate or iso-aspartate. In the 
case of BCL-xL, the majority of deamidated BCL-xL is converted to the iso-
aspartate form, and deamidation can occur at one or both of two asparagine 
residues: N52 and N56. Apoptosis induces deamidation of BCL-xL, and this 
modification was shown to inhibit BCL-xL’s ability to interact with pro-apoptosis 
BH3-only proteins and its ability to modulate apoptosis. Thus, we hypothesized 
that SUMI-1 might regulate the deamidation of BCL-xL (either by blocking its 
deamidation or inducing its re-amidation). To examine this, we treated U2OS 
cells with SUMI-1 or control siRNA and treated a subset of these cells with UV to 
induce apoptosis. Knockdown of SUMI-1 led to a decrease in the 34 kD BCL-xL 
band and a corresponding increase in the 37 kD band. UV radiation induced a 
similar shift in proportions of the two bands, and SUMI-1 further augmented the 
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UV-induced change (Figure 4-19). By comparing the migration of these bands 
with those observed in other publications showing BCL-xL deamidation, it 
appeared that the 34 kD band might correspond to singly-deamidated BCL-xL, 
with the 37 kD band corresponding to deamidation at both asparagine residues. 
To examine this, we generated BCL-xL point mutants to partially mimic 
deamidation at one or both sites (asparagine is replaced with aspartate: N52D 
and/or N66D), and other mutants that cannot be deamidated (asparagine is 
replaced with alanine: N52A and/or N66A). However, the deamidation mimics, 
while migrating higher than the 26 kD predicted size for BCL-xL, migrated at a 
lower apparent size than the 34 kD and 37 kD bands that were modulated by 
RNAi of SUMI-1 (data not shown).  
Because the migration of the bands we observed did not match with the 
predicted molecular weight of BCL-xL or with the migration of deamidation mimic 
BCL-xL mutants, we began to suspect that the BCL-xL antibody used for the 
initial co-IP (S-18, Santa Cruz sc-634) might have detected a nonspecific band 
rather than BCL-xL. To determine whether this band represents BCL-xL, the co-
IP was repeated using additional BCL-xL antibodies for blotting after IP, and a 
reciprocal IP was attempted using several BCL-xL antibodies for the IP and 
blotting for SUMI-1. However, no other BCL-xL antibodies could detect this 
interaction, and a reciprocal IP with BCL-xL antibody failed to pull down SUMI-1 
(data not shown). Thus, it appeared that the BCL-xL S-18 antibody 
nonspecifically recognizes a different protein that co-immunoprecipitates with 
SUMI-1.  
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SUMI-1 interacts with p32, which is the same molecular weight (34 kD) as 
the band recognized by the BCL-xL antibody to interact with SUMI-1. To 
determine whether the 34 kD band recognized by the BCL-xL antibody is p32, a 
co-IP was done in U2OS cells transfected with either p32 siRNA or with plasmids 
expressing various p32 proteins (tagged and untagged; full-length and the 
mature/cleaved form). Whole cell extracts (to represent loading) and samples 
immunoprecipitated with SUMI-1 antibody were resolved by SDS-PAGE and 
blotted with the BCL-xL S-18 antibody. Indeed, the BCL-xL antibody recognized 
tagged and untagged ectopically-expressed p32 and an endogenous band of 
identical molecular weight (Figure 4-20), indicating that this antibody is capable 
of detecting p32. The antigen used by Santa Cruz to produce the BCL-xL S-18 
antibody is an undisclosed peptide located within the first 50 amino acids of the 
BCL-xL sequence. Comparison of this N-terminal region of BCL-xL with the p32 
sequence revealed an area of homology between these proteins that is located 
within the BH4 domain of BCL-xL and near the N-terminus of mature (cleaved) 
p32. This region, which is located within the range of amino acids that Santa 
Cruz indicated were used for producing the Bcl-xL antibody, could potentially 
explain the interaction between this antibody and p32. We conclude that the 
apparent interaction detected between BCL-xL and SUMI-1 was merely an 
artifact caused by nonspecific interaction of p32 with the BCL-xL antibody.  
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SUMI-1 Regulates Mitochondrial Fission-Fusion Dynamics 
As we did not detect any confirmed interactions between BCL-2 family 
proteins and SUMI-1, we considered alternative mechanisms by which SUMI-1 
might regulate BAX. BAX-mediated MOMP is reported to be regulated by 
mitochondrial fusion-fission dynamics (reviewed recently by (Martinou and Youle, 
2011)). To determine whether SUMI-1 affects these processes, we treated cells 
with SUMI-1 siRNA and examined the resulting mitochondrial morphology by 
immunofluorescence staining with the mitochondrial marker Tim23. As shown in 
Figure 4-22A, SUMI-1 knockdown led to mitochondrial fragmentation, with cells 
exhibiting smaller, more punctate mitochondria than found in control cells.  
We next examined whether SUMI-1 overexpression could protect mitochondria 
from the fragmentation that occurs during apoptosis. Cells were treated with 
adenovirus expressing untagged SUMI-1, or empty-vector control, and apoptosis 
was induced with UV. SUMI-1 overexpression greatly reduced UV-induced 
mitochondrial fragmentation (Figure 4-22B). Together, these data suggest that 
SUMI-1 inhibits mitochondrial fragmentation. To determine whether the 
fragmentation induced by SUMI-1 loss resulted from increased fission or 
decreased fusion, we carried out a cell hybrid assay to examine the effect of 
SUMI-1 knockdown on mitochondrial fusion (Figure 4-23A). In this assay, cells 
were first treated with NS or SUMI-1 siRNA. One group of U2OS cells was 
transfected with mt-RED (mKate2 fused with a mitochondrial targeting signal), 
while another group of cells were transfected with mt-GREEN (GFP fused with a 
mitochondrial targeting signal) in order to label mitochondria red or green, 
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respectively. The two groups of cells were then seeded together in the same 
plate, and PEG was applied for 5 minutes to induce fusion of cells. This process 
creates hybrid cells in which a cell with red-labeled mitochondria is merged with a 
cell with green-labeled mitochondria, allowing the two separately-labeled 
mitochondrial groups to intermingle in an intact cell. Under conditions of normal 
mitochondrial fusion, red and green mitochondria fuse, resulting in yellow 
mitochondria (Figure 4-23B, left panel). Without fusion, red and green 
mitochondria remain distinct (Figure 4-23B, right panel). The numbers of hybrid 
cells with and without mitochondrial fusion were tallied and the results plotted. 
SUMI-1 knockdown impaired fusion in the absence of apoptotic stimuli (66% of 
hybrids exhibited fusion compared to 97% for control cells). Consistent with 
previous reports (Lee et al., 2004), we observed a decrease in fusion when cells 
were treated with UV to induce apoptosis (82% of hybrids with fusion), and 
SUMI-1 knockdown augmented UV-induced inhibition of fusion (19% of hybrids 
displayed fusion) (Figure 4-23C). These results suggest that SUMI-1 regulates 
mitochondrial dynamics by inhibiting mitochondrial fusion, providing a plausible 
mechanism for SUMI-1’s regulation of BAX-mediated MOMP and apoptosis.   
 
Discussion 
Mitochondrial outer membrane permeabilization (MOMP) is a critical 
control point during apoptosis and is often the “point of no return,” as cells usually 
proceed to die upon the resulting release of cytochrome c and other 
mitochondrial proteins. For this reason, regulation of MOMP has been an area of 
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intense research, with particular interest in the mechanisms leading to BAX and 
BAK activation and oligomerization. Elucidating these mechanisms may aid in 
our discovery of therapeutics for apoptosis-associated diseases such as immune 
disorders, neurodegenerative disease, and cancer. Identifying novel proteins 
regulating MOMP can enhance our understanding of this process. 
This study establishes SUMI-1 as a novel anti-apoptotic protein residing at 
the mitochondria, where it regulates mitochondrial dynamics, BAX activation, and 
MOMP during apoptosis. Based on the data presented here, we propose a model 
(Figure 4-23) in which SUMI-1 resides on the mitochondria of healthy cells, 
where it protects cells from unnecessary apoptosis by promoting normal 
mitochondrial fusion and inhibiting apoptotic-stimuli-induced BAX activation 
and/or oligomerization. Shortly after treatment with apoptotic stimuli, BAX 
translocates to mitochondria, while SUMI-1, presumably independently, 
translocates from the mitochondria. This exodus of SUMI-1 triggers mitochondrial 
fragmentation, promoting BAX oligomerization and allowing MOMP and 
apoptosis to proceed. These findings provide a localization and function for a 
protein that was previously not well-characterized, contributing to our knowledge 
of the physiological events that take place at the mitochondria to regulate BAX-
mediated MOMP during apoptosis.  
During apoptosis, SUMI-1 translocates from the mitochondria to the 
cytoplasm and nucleus. It is unknown what signal induces this translocation, and 
this would be an interesting area of further investigation. It is also possible that 
SUMI-1 may have an additional role in the cytoplasm and/or nucleus post-
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translocation. Non-mitochondrial SUMI-1 is not required for apoptosis, however, 
as demonstrated by two pieces of evidence. First, transfection with N-terminally-
tagged SUMI-1, which lacks mitochondrial localization (Figure 4-6E), does not 
appear to influence apoptosis (data not shown). More importantly, knockdown of 
SUMI-1 with siRNA promotes rather than inhibits apoptosis, indicating that 
cytoplasmic SUMI-1 is not required for this process. Instead, it is possible that 
non-mitochondrial SUMI-1 may carry out a pro-apoptotic, rather than anti-
apoptotic, function in the cytoplasm and/or nucleus, or it may contribute to 
biochemical or morphological changes observed during apoptosis such as 
phosphatidylserine flipping.  
 Evasion of apoptosis is one of the hallmarks of cancer, and cancers often 
exhibit reduced expression of pro-apoptotic proteins and/or enhanced expression 
of anti-apoptotic proteins (Hanahan and Weinberg, 2000, 2011). According to 
mRNA microarray expression data mined from Oncomine, SUMI-1 is 
overexpressed in a number of cancers derived from different tissues, including 
those of the breast, prostate, lung, kidney, skin, cervix, brain, mesothelium, 
head/neck, pancreas, and in myeloma, lymphoma, and two types of leukemias 
(Table 4-2) (Albino et al., 2008; Andersson et al., 2007; Gordon et al., 2005; 
Haqq et al., 2005; Landi et al., 2008; Pei et al., 2009; Pyeon et al., 2007; Sorlie et 
al., 2003; Storz et al., 2003; Tomlins et al., 2007; Yusenko et al., 2009; Zhan et 
al., 2007). Graphs of these data for three cancers are shown in Figure 4-24. 
Consistent with these reports, we observed increased expression of SUMI-1 
protein in cancer cell lines compared to non-transformed cells (Figure 4-25). This 
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upregulation of SUMI-1 in cancers, along with our data showing that SUMI-1 
knockdown sensitizes cancer cells to chemotherapeutic agents, suggests that 
further research may be warranted to investigate SUMI-1 as a diagnostic marker 
in cancers or as a potential chemosensitizing drug target to enhance current 
cancer therapies. 
 Interestingly, expression of SUMI-1 was reported to be significantly 
downregulated in Alzheimer’s Disease, which is characterized by increased 
apoptosis (Blalock et al., 2004). It is unknown whether this altered expression of 
SUMI-1 contributes to or is merely a consequence of the increased apoptosis 
that occurs in this neurodegenerative disorder, and it is also unknown where 
SUMI-1 might fit into apoptosis pathways that are altered in Alzheimer’s Disease. 
β-amyloid aggregates are thought to induce neuronal apoptosis in part through 
generation of oxidative stress (Ethell and Buhler, 2003). Because SUMI-1 
contains a CHCH domain, which is regulated by redox status in other proteins, it 
is conceivable that SUMI-1 might respond to this change in oxidative stress. 
Future studies may be able to determine whether SUMI-1 plays a causative role 
in Alzheimer’s or other neurodegenerative disorders.  
 
Materials and Methods 
 
Cell Culture, transfections, and apoptotic treatments. U2OS and HeLa cells 
were obtained from ATCC, and mouse embryo fibroblasts were harvested at 
E13.5. All cells were cultured in a 37°C incubator with 5% CO2 in DMEM 
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supplemented with 10% FBS, 100 U/ml penicillin, and 100 g/ml streptomycin. 
DNA transfections were carried out with Fugene-6 or Fugene-HD (Roche), and 
siRNA transfections were performed with Oligofectamine (Invitrogen), according 
to the manufacturers’ instructions. Apoptosis treatments included UVC radiation 
(dosages as indicated) using a Stratalinker® UV Crosslinker (Stratagene), 
cisplatin (10 µg/ml for U2OS and HeLa), doxorubicin (7.5 µM for U2OS), and 
staurosporine (20 µM for U2OS). Where indicated, cells were pretreated for 1 
hour with pan-Caspase inhibitor Q-VD-OPh (R&D Systems, 10 µM for U2OS and 
30 µM for HeLa cells). Subcellular fractionation was carried out as described 
previously (Itahana and Zhang, 2008).  
 
DNA plasmids, adenoviruses, and siRNA. Full-length SUMI-1 cDNA was 
purchased from Open Biosystems (Genbank accession number NM_016139.2), 
and untagged, C-terminally Flag-tagged, and N-terminally Myc-tagged SUMI-1 
were cloned into a pcDNA3.1 vector (Invitrogen). All cloned constructs were 
confirmed by DNA sequencing. Recombinant adenoviruses carrying untagged 
SUMI-1 or GFP were produced using the AdEasy™ XL Adenoviral Vector 
System (Stratagene) according to the manufacturer’s protocol. siRNA duplexes 
targeting SUMI-1 were obtained from Invitrogen (Stealth RNAi™ #HSS167117 
and HSS167119), and nonspecific control siRNA was manufactured by 
Dharmacon.  
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SDS-PAGE, co-immunoprecipitation, and western blotting. Cells were lysed 
in 0.5% NP-40 buffer for straight westerns and either 0.1% NP-40 or 1% CHAPS 
lysis buffer, where indicated, for co-immunoprecipitation (co-IP). Lysates for co-
IP were pre-cleared for 30 minutes with CL-4 beads and incubated in primary 
antibody for 4 hours to overnight followed by incubation in Protein A beads for 1 
hour. Beads were washed 3x, and protein complexes were eluted using 1x SDS-
PAGE sample buffer. Samples were resolved by SDS-PAGE on a 15% 
polyacrylamide gel and transferred onto a 0.2 µM nitrocellulose membrane. 
Membranes were blocked for a minimum of 30 minutes in phosphate-buffered 
saline blocking buffer with 0.1% Tween-20 (PBST) and 5% nonfat dried milk. 
Membranes were incubated for 2 hours to overnight in primary antibody, 
incubated for 1-2 hours in secondary HRP-conjugated antibody, and exposed 
with Supersignal West Pico or Dura (Pierce).  
 
Immunofluorescence imaging. Cells were fixed in 4% paraformaldehyde for 10 
minutes at room temperature and permeabilized in 0.2% Triton X-100 for 5 
minutes at 4°C. Fixed and permeabilized cells were blocked for 30 minutes in 
0.5% BSA blocking buffer in PBS, incubated in primary antibody overnight at 4°C 
with rocking, and incubated with Alexa Fluor® secondary antibodies (488 and 
594 donkey anti-rabbit and donkey anti-mouse) for 30 minutes at room 
temperature with rocking.  Nuclei were stained with DAPI (diamidino-2-
phenylindole), and mitochondria were visualized with MitoTracker™ Red 
(Invitrogen) or other mitochondrial markers where indicated. Cells were mounted 
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in fluorescence mounting medium (Dako) and analyzed using an Olympus IX81 
inverted microscope combined with a SPOT™ digital microscope camera and 
imaging software (SPOT™ Imaging Solutions).  
 
Antibodies. Rabbit anti-SUMI-1 antibody was produced by immunizing rabbits 
(performed by PRF&L, Canadensis, PA) with a KLH-conjugated peptide antigen 
corresponding to amino acids 94-108 of SUMI-1. Serum was affinity purified, and 
antibody specificity was tested by western blotting and immunofluorescence 
staining with SUMI-1 knockdown (Figure 4-5). The following antibodies were 
purchased commercially: actin (Chemicon), PARP (C2-10, BD Pharmingen), 
HSP70/GRP75 (H-155, Santa Cruz), cytochrome c (6H2.B4, BD Pharmingen), 
Tim23 (BD Transduction Laboratories), Active BAX (6A7, BD Biosciences), BIM 
(C34C5, Cell Signaling), BCL-2 (50E3, Cell Signaling), BAX (Cell Signaling, 
D2E11), and BCL-xL (S-18, Santa Cruz sc-634;  54H6, Cell Signaling). 
 
Immunogold electron microscopy. Experiments were carried out by the 
Microscopy Services Laboratory in the Department of Pathology and Laboratory 
Medicine at the University of North Carolina at Chapel Hill. Cells grown on Nunc 
Permanox chamberslides were fixed with 4% paraformaldehyde in 0.15 M 
sodium cacodylate, pH 7.4, for 1 hour. Using a pre-embedding immunogold/silver 
staining protocol (Yi et al., 2001), cells were incubated in primary antibody (1:50 
dilution of rabbit anti-SUMI-1), followed by secondary antibody incubation in goat 
anti-rabbit IgG 0.8nm immunogold (Aurion, Electron Microscopy Sciences).  After 
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silver enhancement, cells were processed and embedded in Polybed 812 epoxy 
resin (Polysciences, Inc., Warrington, PA).  70 nm ultrathin sections were cut, 
mounted on copper grids, and post-stained with 4% uranyl acetate and Reynolds’ 
lead citrate (Reynolds, 1963).  Sections were observed using a LEO EM-910 
transmission electron microscope operating at 80kV (LEO Electron Microscopy, 
Thornwood, NY), and images were taken using a Gatan Orius SC1000 CCD 
camera with Digital Micrograph 3.11.0 (Gatan, Inc., Pleasanton, CA).  
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Table 4-1. Conservation among SUMI-1 orthologs. 
Percentage of amino acid identity is shown for eight orthologs of the SUMI-1 
protein.   
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Figure 4-1. Sequence alignment for SUMI-1 orthologs. 
CLUSTALW protein sequence alignment of human SUMI-1 protein and SUMI-1 
orthologs in the eight species shown in Table 4-1. Darker shading indicates 
greater sequence similarity.  
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Figure 4-2. Domain structure of SUMI-1.   
A) Schematic representation of the SUMI-1 protein, with putative mitochondrial 
targeting signal (MitoProt), transmembrane domain (TMpred), CHCH (coiled-coil-
helix coiled-coil-helix) domain, and intermembrane space targeting sequence 
(ITS) shown. The transmembrane domain is highly conserved across SUMI-1 
orthologs. The CHCH domain is comprised of four evenly-spaced cysteines, with 
positions indicated. The predicted transmembrane domain is located in a highly-
conserved region of the SUMI-1 protein. 
B) The SUMI-1 mitochondrial intermembrane space targeting signal (ITS) and 
the consensus ITS for Mia40-mediated intermembrane space import. 
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Figure 4-3. Predicted intramolecular disulfide bond formation for SUMI-1. 
Analysis of the SUMI-1 amino acid sequence by DiANNA 1.1 predicts the 
formation of intramolecular disulfide bonds between cysteines 1 and 3 (C1-C3) of 
the CHCH domain, and between cysteines 2 and 4 (C2-C4), creating a loop in 
the CHCH domain as illustrated above (drawing not to scale).   
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Figure 4-4.  Antibody design for SUMI-1. 
A) Schematic of SUMI-1 protein showing approximate location of the peptide 
antigens (SU-94 and SU-124) selected for production of SUMI-1 rabbit polyclonal 
antibodies. Red triangles indicate the approximate positions of the selected 
peptides. 
B) The SUMI-1 protein sequence with the two selected peptide antigens shown 
in red and underlined. 
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Figure 4-5. SUMI-1 antibody effectiveness and specificity 
A) Whole-membrane western blot showing specificity and effectiveness for 
purified rabbit polyclonal antibody targeting SUMI-1 (SU-94).  
B) Immunofluorescence signal detected with SUMI-1 antibody is specific to 
SUMI-1. Cells were treated with either control lentivirus (sh-NS) or lentivirus 
expressing SUMI-1 shRNA (sh-SUMI-1), fixed with formaldehyde, permeabilized, 
and immunofluorescence-stained with SUMI-1 antibody. Phase-contrast images 
are shown below. Note that fluorescence signal is greatly diminished upon SUMI-
1 knockdown (top right panel). 
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Figure 4-6. Immunofluorescence imaging demonstrates mitochondrial 
localization of SUMI-1.   
A) C-terminally-tagged SUMI-1-Flag localizes to the mitochondria, as indicated 
by costaining with MitoTracker™ dye. SUMI-1-Flag was detected by 
immunofluorescence with Flag antibody. 
B) Mitochondrial localization of endogenous SUMI-1 in U2OS cells detected by 
immunofluorescence with SUMI-1 antibody, demonstrated by costaining for 
mitochondrial marker cytochrome c.  
C) Mitochondrial localization of SUMI-1 in HeLa cells detected as in (B).  
D) Mitochondrial localization of SUMI-1 in MEF (mouse embryo fibroblast) cells 
detected as in (B). 
E) Presence of an N-terminal tag disrupts mitochondrial localization of SUMI-1. 
Cells were transfected with Myc-SUMI-1 and stained with anti-Myc antibody. 
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Figure 4-7. Subcellular fractionation of SUMI-1.   
Untreated U2OS cells were fractionated using a differential detergent method. 
SUMI-1 is present in the mitochondria-enriched heavy membrane fraction, with 
three replicates shown for each fraction. Hsp70 is a marker for the mitochondrial 
fraction, and actin is a marker for the cytoplasmic fraction (Cyto, cytoplasm; Mito, 
mitochondria). 
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Figure 4-8. Immunogold-EM localization of SUMI-1.   
(Left) Pre-embedding immunogold staining of endogenous SUMI-1 visualized by 
electron microscopy. Gold beads corresponding to endogenous SUMI-1 can be 
seen around perimeter of mitochondria. One example is designated with an 
arrow. (Cyt, cytoplasm; Mito, mitochondria). (Center) Immunogold staining with 
an isotype antibody is shown as a negative control. (Right) Post-embedding 
immunogold staining shows that endogenous SUMI-1 is also present inside the 
mitochondria as well as along the outer membrane.  
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Figure 4-9. SUMI-1 knockdown promotes apoptotic cell death.   
A) SUMI-1 knockdown sensitizes U2OS cells to apoptosis induced by a variety of 
agents. Cells were treated with indicated siRNA for 48 hours and treated to 
induce apoptosis with cisplatin (CIS, 10 µg/ml for 18 h), UV (25 mJ/cm
2
 for 4 h), 
doxorubicin (DOX, 7.5 µM for 18 h), or staurosporine (STS, 20 µM for 18 h). The 
number of cells surviving each treatment is shown as a percentage of si-NS 
control and is an average of cells counted from at least 4 fields for each 
condition. Error bars indicate standard deviation. 
B) SUMI-1 knockdown sensitizes HeLa cells to apoptosis induced by cisplatin 
(CIS, 10 µg/ml for 18 h) and UV (2.5 mJ/cm
2
 for 18 h). Cells were treated and 
quantified as in (A). 
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Figure 4-10. SUMI-1 knockdown enhances cleavage of PARP and Caspase-
3. 
A) SUMI-1 knockdown enhances PARP cleavage during apoptosis. HeLa cells 
were treated with indicated siRNA for 48 h and treated where indicated with UV 
(3 mJ/cm
2
 for 18 h) to induce apoptosis. Actin is shown as a loading control.  
B) SUMI-1 knockdown increases cleavage of Caspase-3 during apoptosis. U2OS 
cells were treated with indicated siRNA for 48 h and treated where indicated with 
UV (6 mJ/cm
2
 for 18 h) to induce apoptosis. Actin is shown as a loading control.  
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Figure 4-11. SUMI-1 knockdown promotes apoptotic cell death.   
(A) SUMI-1 knockdown sensitizes U2OS cells to UV-induced cell death. Phase-
contrast images (10x) are shown of cells treated for 48 hours with nonspecific 
siRNA (si-NS) or SUMI-1 siRNA (si-SUMI-1), with or without UV treatment (25 
mJ/cm
2
 for 3 hours). Floating (dead) cells appear rounded and white. 
(B) Apoptotic membrane blebbing is evident at higher magnification (40x) in cells 
from (A) treated with SUMI-1 siRNA and UV. Cells displaying blebbing are 
indicated with arrows. 
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Figure 4-12. SUMI-1 overexpression protects against apoptotic cell death.   
A) Overexpression of untagged SUMI-1 protects U2OS cells from apoptosis. 
Cells were treated for 24 h with control adenovirus (expressing GFP) or 
adenovirus expressing untagged SUMI-1 and then treated with UV to induce 
apoptosis (25 mJ/cm
2
 for 8 hours). The number of cells surviving is shown as a 
percentage of Ad-GFP control.  
B) SUMI-1 overexpression inhibits PARP cleavage during apoptosis. HeLa cells 
were treated with indicated adenovirus for 24 hours (Ctl, Ad-GFP; SU, SUMI-1) 
and then treated with UV (25 mJ/cm
2
 for 8 hours) to induce apoptosis. Actin is 
shown as a loading control.  
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Figure 4-13. SUMI-1 translocates from mitochondria during apoptosis.   
A) SUMI-1 translocates from mitochondria during apoptosis. U2OS cells were pretreated 
with QVD for 1 h and treated with UV to induce apoptosis (6 mJ/cm
2 
for 24 h), where 
indicated. Endogenous SUMI-1 was detected by immunofluorescence staining.  
B) A higher-magnification immunofluorescence image of endogenous SUMI-1 (green) 
and endogenous cytochrome c (red) together in UV-treated (6 mJ/cm
2 
for 12 h) U2OS 
cells reveals that cytochrome c can be observed in mitochondria from which SUMI-1 has 
already translocated.  
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Figure 4-14. SUMI-1 translocates from mitochondria prior to cytochrome c.   
A) SUMI-1 translocates prior to cytochrome c during apoptosis. HeLa cells were 
treated with UV (6 mJ/cm
2
 for 12 h) to induce apoptosis, and 
immunofluorescence staining was done for endogenous SUMI-1 (green) and 
endogenous cytochrome c (red). Arrows in top row indicate a cell in which SUMI-
1 has translocated but cytochrome c is retained in mitochondria. Arrows in 
bottom row indicate a cell in which both SUMI-1 and cytochrome c have 
translocated from mitochondria.  
B) SUMI-1 translocates more rapidly than cytochrome c over a time course. 
U2OS cells were pretreated with Caspase inhibitor QVD (10 µM for 1 h) to 
preserve cell survival post-MOMP, treated with UV (25 mJ/cm
2
) to induce 
apoptosis, and fixed at indicated time points. Immunofluorescence staining was 
done for endogenous SUMI-1 and cytochrome c. The percentages of cells with 
translocated SUMI-1 and cytochrome c were quantified at each time point and 
shown on graph as averages from 4 fields. Error bars indicate standard deviation 
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Figure 4-15. SUMI-1 knockdown regulates mitochondrial outer membrane 
permeabilization.   
A) SUMI-1 knockdown increases the kinetics of MOMP as indicated by 
cytochrome c release. U2OS cells were treated with indicated siRNA (NS, 
nonspecific) for 48 hours, pretreated with Caspase inhibitor QVD to preserve cell 
survival post-MOMP, and treated to induce apoptosis where indicated (UV, 25 
mJ/cm
2
 for 4 hours) followed by immunofluorescence staining for endogenous 
cytochrome c. The panel on the right shows an example of a cell (demarcated 
with dotted line) with released cytochrome c, which appears diffuse throughout 
the cytoplasm and nucleus. Note that cells treated with SUMI-1 siRNA exhibit a 
greater proportion of cells with cytochrome c release. 
(B) SUMI-1 knockdown increases the kinetics of MOMP over a time course. 
U2OS cells were treated as in (A) and fixed at various time points after UV 
treatment. Following immunofluorescence staining for endogenous cytochrome c, 
the percentages of cells exhibiting released cytochrome c were quantified at 
indicated time points and shown on the graph as averages from at least 4 fields. 
Error bars indicate standard deviation.   
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Figure 4-16. SUMI-1 knockdown regulates BAX activation.   
A) SUMI-1 knockdown increases Bax activation during apoptosis. U2OS cells 
were treated with indicated siRNA (NS, nonspecific) for 48 h followed by 
treatment to induce apoptosis (UV, 6 mJ/cm
2
) where indicated. Cells were fixed 
after 24 h and stained for active Bax (6A7). Red staining indicates presence of 
active, oligomerized Bax that has accumulated on mitochondria.  
B) Bax activation correlates with SUMI-1 translocation in U2OS cells. Cells were 
treated with UV (6 mJ/cm
2
 for 24 h) to induce apoptosis. Immunofluorescence 
staining was done for endogenous SUMI-1 (green) and active Bax 6A7 (red). 
Active Bax is observed only in cells in which SUMI-1 has translocated from 
mitochondria. Nuclei were stained with DAPI. 
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Figure 4-17. SUMI-1 knockdown regulates BAX oligomerization. 
SUMI-1 knockdown increases trypsin-resistant, oligomerized BAX (TR-Bax). A 
trypsin-resistance assay was carried out on isolated mitochondria after treating 
cells with indicated siRNA for 48 hours followed by UV where indicated. 
Mitochondria were treated with trypsin to digest monomeric BAX, lysed, resolved 
by SDS-PAGE and assayed by immunoblotting alongside whole cell lysates.    
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Figure 4-18. SUMI-1 co-immunoprecipitates with a protein recognized by 
BCL-xL S-18 antibody.   
A) Co-immunoprecipitation (co-IP) in untreated cells using SUMI-1 antibody (SU-
94, designated as SU above) or IgG control. Complexes were resolved by SDS-
PAGE and blotted with indicated antibodies. No interaction was found between 
SUMI-1 and BCL-2 or BIM, but apparent binding was detected between SUMI-1 
and BCL-xL (right panel).  
B) Co-IP in untreated U2OS cells or U2OS cells stably-expressing sh-SUMI-1. 
Complexes were resolved by SDS-PAGE and blotted with indicated antibodies. 
IP for SUMI-1 with two different antibodies (AB 1, SU-94; AB 2, Proteintech) 
pulled down a protein migrating at 34 kD that is detected with the BCL-xL S-18 
antibody (Santa Cruz, sc-634).  Co-immunoprecipitation of this protein was 
diminished by shRNA inhibition of SUMI-1, demonstrating that the protein does 
not interact nonspecifically with the SUMI-1 antibodies.  
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Figure 4-19. SUMI-1 siRNA induces shift in proportion of 34 kD and 37 kD 
bands detected by BCL-xL S-18 antibody.  
U2OS cells were treated with SUMI-1 siRNA or nonspecific (NS) control siRNA 
and treated with UV where indicated to induce apoptosis. Lysates were resolved 
by SDS-PAGE and blotted with indicated antibodies. Note that siRNA inhibition of 
SUMI-1 induces a decrease in the 34 kD band detected by the BCL-xL S-18 
antibody, and a corresponding increase in the 37 kD band. The 34 kD and 37 kD 
bands were later identified to be p32 (Figure 4-19). Apoptosis-inducing UV 
treatment causes a similar shift, and knockdown of SUMI-1 further augments this 
shift.  
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Figure 4-20. Nonspecific band recognized by BCL-xL S-18 antibody is p32. 
U2OS cells were transfected with various agents to inhibit or overexpress p32 
and subjected to IP with SUMI-1 antibody (C-94). Loading and IP samples were 
resolved by SDS-PAGE and blotted with BCL-xL antibody (S-18, Santa Cruz sc-
634). Note that the BCL-xL S-18 antibody recognizes both endogenous p32 and 
various ectopically-expressed tagged p32 proteins. (si-p32, p32 siRNA; Ad-p32, 
adenovirus expressing untagged p32; p32-Flag (S), stable transfection of p32-
Flag; p32-Flag (T), transient transfection of p32-Flag;  Flag-p32m, Flag-tagged 
mature/cleaved p32; Myc3-p32; Myc3-tagged full-length p32; Myc3-p32m, Myc3-
tagged mature/cleaved p32). 
 
This experiment was performed by Yong Liu. 
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Figure 4-21. Region of homology between p32 and BH4 domain of BCL-xL. 
CLUSTAL 2.1 sequence alignment indicates a 20-residue region of similarity 
between p32 and BCL-xL corresponding to the N-terminal BH4 domain of BCL-
xL. This region includes a motif (VDFLS) that is identical between the proteins. 
Dots indicate similarity, and colons indicate strong similarity. (Red = small; blue = 
acidic; magenta = basic; green = hydroxyl + sulfhydryl + amine + G).  
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Figure 4-22. SUMI-1 inhibits mitochondrial fragmentation.   
A) SUMI-1 knockdown leads to mitochondrial fragmentation. U2OS cells were 
treated with indicated siRNA for 48 hours and subjected to UV (25 mJ/cm2 for 3 
h) to induce apoptosis. Immunofluorescence staining was carried out for a 
mitochondrial marker Tim23 (red) and DAPI to indicate nuclei (blue). Cells 
treated with SUMI-1 siRNA showed increased mitochondrial fragmentation 
(right).  
B) SUMI-1 overexpression protects cells from UV-induced mitochondrial 
fragmentation. U2OS cells were treated with adenovirus expressing untagged 
SUMI-1 or empty adenovirus (vector) where indicated, and 24 h later treated with 
UV (25 mJ/cm2 for 3 h) where indicated. Note that mitochondria remain 
elongated in cells overexpressing SUMI-1. 
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Figure 4-23. SUMI-1 regulates mitochondrial fusion.   
A) In a cell hybrid mitochondrial fusion assay, one plate of cells is transfected 
with mitochondrial-targeted GFP (mt-GFP) to label mitochondria green, and 
another plate is transfected with mt-mKate2 to label mitochondria red. The cells 
are then plated together and treated with PEG for five min. to create cell hybrids 
containing red and green mitochondria. If fusion ensues, regions with yellow 
mitochondria (containing both red and green fluorescent proteins) are observed. 
Without fusion, red and green mitochondria remain distinct.  
B) SUMI-1 knockdown impairs mitochondrial fusion. Cells were treated with 
indicated siRNA for 48 hours and treated as described in (A). Cells were treated 
with UV (25 mJ/m
2
) where indicated, fixed after 2.5 h, and analyzed. An example 
of a cell hybrid exhibiting mitochondrial fusion (contains yellow mitochondria) is 
shown on the left (boxes enclose areas displaying fused, yellow, mitochondria). A 
hybrid lacking fusion is shown on the right.  
C) Cells were treated as in (B), and hybrids with mitochondrial fusion (determined 
by presence of yellow color) were quantified and shown on graph as a 
percentage of total hybrids. Error bars indicate standard deviation.  
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Figure 4-24. Model for regulation of MOMP by SUMI-1.   
In unstressed cells, SUMI-1 resides at the mitochondrial membrane, where it 
keeps mitochondrial fusion-fission dynamics in balance. Upon treatment with 
apoptotic stimuli such as UV, SUMI-1 translocates from the mitochondria, while 
Bax becomes activated by BH3-only proteins and accumulates at the 
mitochondria, likely independent from SUMI-1. Following SUMI-1 translocation, 
mitochondrial fusion is inhibited while mitochondrial fission continues 
unperturbed, leading to mitochondrial fragmentation. This fragmentation 
promotes Bax oligomerization, leading to MOMP, cytochrome c release, and 
ultimately, apoptosis.  
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Figure 4-25. Increased expression of SUMI-1 in cancers.   
Data obtained from Oncomine for expression of SUMI-1 mRNA in three types of 
cancer compared to corresponding normal tissues. SUMI-1 expression is 
represented as a log2 median-centered ratio in normal tissue (light grey bars) 
and cancerous tissue (dark grey bars). Each bar represents an individual sample.  
A) Tomlins Prostate: Average fold change is 2.130, and P-value is 1.98E-4.  
B) Haqq Melanoma: Average fold change is 4.163, and P-value is 4.77E-4.  
C) Andersson Leukemia: Average fold change is 2.913, and P-value is 1.56E-5.  
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Cancer Type 
Fold 
Increase P-Value Dataset 
Breast, ductal carcinoma 1.754 4.10E-10 Sorlie 2003 
Cervical cancer 1.656 2.00E-03 Pyeon 2007 
Glioblastoma 1.579 5.57E-05 Liang 2005 
Leukemia, acute myeloid  2.032 2.16E-05 Andersson 2007 
Leukemia, childhood T-cell acute 
lymphoblastic  
2.913 1.56E-05 Andersson 2007 
Lung adenocarcinoma 1.564 3.07E-13 Landi 2008 
Lymphoma, diffuse B-cell 1.846 1.00E-02 Storz 2003 
Melanoma 4.163 4.77E-04 Haqq 2005 
Mesothelioma, pleural malignant  2.018 1.62E-06 Gordon 2005 
Myeloma, smoldering 2.018 3.23E-05 Zhan 2007 
Neuroblastoma 1.755 8.76E-04 Albino 2008 
Oral cavity carcinoma 2.827 2.05E-06 Pyeon 2007 
Oropharyngeal carcinoma 2.325 3.85E-06 Pyeon 2007 
Pancreatic carcinoma 1.520 3.48E-05 Pei 2009 
Prostate carcinoma 2.130 1.98E-04 Tomlins 2007 
Renal cell carcinoma, papillary 1.591 1.30E-04 Yusenko 2009 
Tongue carcinoma 2.231 1.12E-05 Pyeon 2007 
 
 
Table 4-2. Increased expression of SUMI-1 in cancers. 
SUMI-1 mRNA microarray expression data mined from Oncomine for cancerous 
tissues compared to corresponding normal tissues. Cancers with at least 1.5-fold 
overexpression of SUMI-1 compared to normal tissue and a P-value ≤ 0.01 are 
shown.   
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Figure 4-26. Increased expression of SUMI-1 in cancerous compared to 
non-cancerous cell lines. 
Expression of SUMI-1 was assessed in a panel of lysates from cultured human 
cell lines. Cells were lysed in 0.5% NP-40 lysis buffer, resolved by SDS-PAGE, 
and blotted with an antibody for SUMI-1 (C-94) and actin as loading control. Note 
that SUMI-1 expression is lowest in the two non-cancerous cell lines (BJ, normal 
skin fibroblast; WI38, normal embryonic lung). 
 
 
 
  
 
 
 
 
 
CHAPTER V 
 
 
REGULATION OF SUMI-1 DURING APOPTOSIS 
 
Introduction 
 We show that SUMI-1 translocates during apoptosis prior to cytochrome c 
release in order to regulate MOMP. However, the SUMI-1 protein level also 
appears to decrease during apoptosis, suggesting that in addition to 
translocation, SUMI-1 may be regulated by degradation during apoptosis. Thus, 
we carried out experiments to determine whether SUMI-1 may be regulated by 
degradation and/or another mechanism, in addition to translocation, during 
apoptosis.  
 
Apoptotic Stimuli Reduce Level of Endogenous SUMI-1 
In our previous experiments, we observed that the level of endogenous 
SUMI-1 protein decreases during apoptosis induced by UV radiation and 
cisplatin. To examine this in more detail, apoptosis was induced in U2OS cells 
using a variety of agents, and the effect on SUMI-1 level was examined. As 
shown in Figure 5-1 (left panel), the level of endogenous SUMI-1 in U2OS cells 
was decreased following administration of UV, staurosporine, doxorubicin, 
cisplatin, vinblastine, and taxol. To determine whether this effect could be 
reproduced in another cell type, we examined HeLa cells with and without 
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apoptosis induced by UV. As in U2OS cells, UV treatment decreased the level of 
endogenous SUMI-1 (Figure 5-1, right panel). 
 
SUMI-1 is Not Degraded by the Proteasome During Apoptosis 
Protein degradation is usually carried out by the proteasome—a large 
protein complex that breaks down proteins that are no longer needed by the cell 
or that must be eliminated in order to regulate processes such as cell cycle 
control or apoptosis. Proteins are targeted for proteasomal degradation by 
covalent addition of the small protein ubiquitin to specific lysine residues on the 
target protein, a process carried out by ubiquitin-conjugating enzymes (E1, E2, 
and E3 ubiquitin ligases). When multiple ubiquitin molecules have been added to 
a single residue, the resulting polyubiquitin chain directs the target protein to the 
proteasome, which cleaves the protein into peptides 7 to 8 amino acids in length. 
These short peptides can be further broken down into individual amino acids and 
recycled for use in translation of new proteins (Baumeister et al., 1998).  
We carried out experiments to determine whether SUMI-1 is degraded 
proteasomally, using the potent and specific inhibitor MG132, which blocks the 
ability of the 26S proteasome to degrade proteins (Tsubuki et al., 1996). If SUMI-
1 is normally degraded by the proteasome during apoptosis, MG132 should block 
the associated decrease in SUMI-1 protein level. To test this, we treated U2OS 
and HeLa cells with MG132 (20 uM) for 1 hour followed by UV (250 J/m2) for 4 h 
and examined the level of endogenous SUMI-1 as well as positive controls p53 
and Mdm2, which are known to be degraded by the proteasome. While MG132 
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effectively prevented degradation of p53 and Mdm2, it did not block the decrease 
in SUMI-1 level observed during UV-induced apoptosis. In fact, MG132 
augmented the UV-induced decrease in SUMI-1 level (Figure 5-2, compare lanes 
3-4, and 7-8), and treatment with MG132 alone also significantly decreased the 
SUMI-1 level (Figure 5-2, compare lanes 1-2, and lanes 5-6.). This MG132-
induced decrease in SUMI-1 level is not surprising, as MG132 and other 
proteasome inhibitors are known to induce apoptosis (Drexler, 1997), and, as 
shown in Figure 5-1, the level of endogenous SUMI-1 decreases during 
apoptosis. Based on the data presented here, it is unlikely that the apoptosis-
associated decrease in SUMI-1 is due to proteasomal degradation.  
 
SUMI-1 is Potentially Regulated by Oligomerization 
 We next examined oligomerization as a possible explanation for the 
decrease in SUMI-1 level observed during apoptosis. That is, SUMI-1 may not be 
degraded but may instead form SDS-resistant oligomers. This phenomenon 
would reduce the quantity of monomeric (17 kD) SUMI-1 observed by western 
blotting. Indeed, SUMI-1 contains a CHCH (coiled-coil-helix-coiled-coil-helix) 
domain that is known to mediate SDS-resistant homo- and hetero-
oligomerization in other proteins containing this domain. This oligomer formation 
is mediated by covalent disulfide bonds between conserved cysteines in the 
CHCH domain and has been studied most extensively in the CHCH-domain-
containing protein Cox17 (Arnesano et al., 2005), which interacts with SCO-1 to 
feed copper ions into the COX (cytochrome c oxidase) complex during COX 
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assembly (Banci et al., 2008a; Banci et al., 2008b). Another CHCH-domain 
protein, Mia40, mediates transport of mitochondrial proteins into the 
intermembrane space by forming transient disulfide-mediated hetero-oligomers 
with other cysteine-containing proteins as they are imported (Sideris et al., 2009). 
In both cases, formation of these oligomers depends on the reductive-oxidative 
(RedOx) status of the proteins’ immediate environment (Arnesano et al., 2005), 
as bond formation requires oxidation of the cysteines’ thiol groups. In a fully-
reduced environment, cysteines are not capable of forming disulfide bonds with 
one another, while in a more oxidative environment, bonds can form either 
between specific cysteines on another protein to mediate homo- or hetero-
oligomerization, or between cysteines on the same protein to induce changes in 
tertiary structure such as hairpin formations. Which of these cysteines interact, 
and which tertiary or quaternary structure results (i.e. intramolecular folding, 
homo-oligomerization, or hetero-oligomerization), depends largely on the extent 
of oxidation (Arnesano et al., 2005) but is also affected by features of the 
surrounding amino acid sequence such as distance between adjacent cysteines.  
 To determine whether SUMI-1 might oligomerize during apoptosis, we 
carried out a whole-membrane western blot with SUMI-1 antibody after treating 
U2OS cells with increasing doses of UV radiation. As we observed previously, 
the 17 kD band disappeared upon UV radiation in a dose-dependent manner. 
Interestingly, we observed a corresponding increase in a higher molecular weight 
(HMW) band (approximately 65 kD in size) detected by the SUMI-1 antibody 
(Figure 5-3A). To determine whether the HMW band could represent an SDS-
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resistant oligomer of SUMI-1, we assessed whether the band would disappear 
under harsher denaturing conditions. Often, disulfide bond-mediated oligomers 
are not reduced by standard SDS-PAGE, even in the presence of denaturing 
agents such as DTT. In order to reduce this type of oligomer, an additional 
denaturing agent must typically be applied, such as extended heating, deep-
freeze/thaw cycles, or treatment with a denaturing chemical such as urea. 
Stronger disulfide bonds require harsher denaturing agents, and the type of 
denaturing agent required to break these bonds can be used as a quantitative 
measure of the disulfide bond’s strength. In the first 2 lanes of Figure 5-3B, 
U2OS cells were either left untreated or treated with UV (10 mJ/cm2), with both 
samples heated in SDS-DTT sample buffer for the standard time (3 minutes). 
Consistent with our previous observations, UV radiation led to a decrease in the 
17 kD band and an increase in the 65 kD band (compare lanes 1 and 2). In the 
third lane, a portion of the same lysate used for lane 2 (UV-treated) was heated 
for 60 minutes instead of 3 minutes. This extended heating resulted in a partial 
decrease in the 65 kD band and a partial increase in the 17 kD band (Figure 5-
3B, compare lanes 2 and 3).  
 In addition, we attempted to determine whether overexpression of SUMI-1 
could increase the higher molecular weight bands detected by the SUMI-1 
antibody. We transfected cells with a pShuttle plasmid expressing untagged 
SUMI-1 or an empty vector as a negative control. To our surprise, we did not 
observe any increase in the 17 kD band, but only in the 65 kD band detected by 
the SUMI-1 antibody (Figure 5-4). The reason for these results is not clear, but it 
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is possible that SUMI-1 preferentially takes the oligomerized form and that there 
is a limit to the quantity of monomeric SUMI-1 that can reside in a cell, or that the 
experimental conditions (e.g. excessive oxidation of lysis buffer) induced 
oligomerization. Alternatively, it is possible that the pShuttle vector used for 
expressing SUMI-1 did not express properly, but this would not explain the 
increase in the HMW band detected by the SUMI-1 antibody following 
transfection. This same plasmid was used later to generate adenovirus 
expressing untagged SUMI-1. This adenovirus successfully expressed the 17 kD 
SUMI-1 band (Figure 4-12), but its effect on higher molecular weight bands has 
not yet been examined. The HMW band was also examined after treatment with 
SUMI-1 siRNA, which failed to decrease this band (data not shown). However, 
siRNA does not induce complete knockdown of SUMI-1, and it is possible that 
the oligomerized form is more stable or is the preferred state for SUMI-1, as 
suggested by the overexpression data. 
 Together, the experiment showing that the proteasome inhibitor MG-132 
does not prevent the decrease in the 17 kD SUMI-1 band, and the data showing 
that UV induces a dose-dependent increase in a HMW band that corresponds to 
a decrease in the 17 kD band, partially recovered by further denaturation of the 
lysate, suggest that SUMI-1 is not proteasomally degraded during apoptosis and 
may instead form SDS-resistant oligomers. However, additional experiments are 
needed to confirm this finding or to determine whether SUMI-1 might be 
regulated in a different manner.  
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Discussion 
 The level of SUMI-1 protein visualized by western blotting decreases 
during apoptosis induced by a variety of apoptotic stimuli. Here, we examined 
potential reasons for this apparent reduction in SUMI-1 level. We show that this 
decrease is not affected by the proteasome inhibitor MG132, suggesting that 
SUMI-1 is not degraded during apoptosis, at least not by the ubiquitin-
proteasome pathway. Instead, we observed that a higher molecular weight band 
(approximately 65 kD) detected by purified SUMI-1 antibody is induced by UV 
radiation, and this HMW band appears in a dose-dependent manner 
corresponding to a decrease in the 17 kD band. These data suggest that SUMI-1 
may form oligomers during apoptosis. These HMW complexes could represent 
SUMI-1 homo-oligomers; in this case, the molecular weight (approximately 65-70 
kD) appears most consistent with that of a SUMI-1 tetramer, which would be 
predicted to migrate at approximately 68 kD, although oligomers can potentially 
migrate more rapidly or slowly than expected. Alternatively, it is possible that 
SUMI-1 does not homo-oligomerize but forms disulfide-bond mediated 
complexes with one or more unknown proteins.   
 It is also possible that the HMW band detected by the SUMI-1 antibody is 
not oligomerized SUMI-1, but another protein detected nonspecifically by the 
SUMI-1 antibody. This alternative is unlikely, as it cannot explain our finding that 
further denaturation of lysate from UV-treated cells caused a partial decrease in 
the HMW band and a corresponding increase in the 17 kD band (Figure 5-3). 
Nevertheless, in an attempt to rule out the possibility that this band may 
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represent a nonspecific protein, we carried out several additional experiments, 
but results have been inconclusive. SDS-resistant oligomers are notoriously 
difficult to study—Artificial oligomers can be formed by oxidation of lysates, for 
example, and oligomerization status can be quite sensitive to conditions of cell 
culture and lysis. When repeating an experiment under seemingly identical 
conditions, proportions of oligomers and monomers can change. Sometimes 
additional bands are observed by western blotting with SUMI-1 antibody, 
migrating at approximately 40-45 kD and 110-120 kD; we have not been able to 
discern a pattern for the appearance of these bands. In an attempt to preserve 
the native status of disulfide bonds in the cell and avoid introducing artificial ones 
during cell lysis, we attempted to treat cells with N-ethylmaleimide (NEM) upon 
addition of lysis buffer. NEM is a small alkene that interacts irreversibly with 
thiols, “capping” them so that they can no longer interact with other cysteines to 
form disulfide bonds. Thus, addition of NEM during lysis should prevent formation 
of new disulfide bonds that were not already present in the intact cell. However, 
when NEM was applied to our lysis buffer prior to SDS-PAGE, we paradoxically 
observed a dramatic decrease in the 17 kD (monomer) band along with 
disappearance of the putative oligomer band and appearance of several new 
HMW band of various sizes (data not shown). We have not been able to explain 
these results. One possibility is that NEM alters the cell’s redox status by 
inactivating redox-regulating proteins such as glutathione, many of which contain 
cysteines, inducing SUMI-1 oligomerization. Another method for determining 
whether the HMW band is an oligomer is by detecting this band with two different 
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SUMI-1 antibodies targeting different regions of the protein. We attempted to 
detect the 65 kD band with another antibody that we produced, and we were 
unable to detect it. However, the antigen for this antibody is located in the center 
of the oligomerization (CHCH) domain, which is not likely to be exposed to the 
antibody when the protein is oligomerized. This issue could potentially be 
addressed by using another antibody toward SUMI-1. In summary, given our 
findings that 1) SUMI-1 is not proteasomally degraded during apoptosis, 2) a 
HMW band is detected by the SUMI-1 antibody in a dose-dependent manner 
corresponding to a decrease in the 17 kD band, and 3) Additional denaturation of 
cell lysate causes a partial decrease in the HMW band and a corresponding 
increase in the 17 kD band, the most logical explanation is that SUMI-1 
oligomerizes during apoptosis. Furthermore, the CHCH domain found in SUMI-1 
is known to mediate SDS-resistant oligomerization in other proteins. 
Nevertheless, it remains possible that SUMI-1 is not regulated by 
oligomerization. Further studies could be carried out to address this issue, such 
as detecting the same HMW band with another SUMI-1 antibody.  
 If oligomerization of SUMI-1 does not occur during apoptosis, another 
mechanism must account for the apparent decrease in the 17 kD band during 
apoptosis. One alternative is that SUMI-1 is transcriptionally regulated—
Signaling pathways induced by apoptotic stimuli may block transcription of SUMI-
1 mRNA. While we have not formally examined this idea, it is not likely that 
SUMI-1 is regulated in this manner, as the existing SUMI-1 in the cell would still 
have to be degraded in order for impaired transcription to result in reduced 
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protein so rapidly, and SUMI-1 is too stable for the degradation to occur as 
rapidly as 18 hours; while a formal half-life assay has not been performed, when 
SUMI-1 is targeted with RNAi, a significant decrease in SUMI-1 level is not 
observed until 48 hours after siRNA transfection, indicating that SUMI-1 is a 
relatively stable. Thus, impaired transcription cannot account for the decrease of 
SUMI-1 in this time frame unless degradation is also induced. It is possible that 
SUMI-1 is degraded through an unknown, non-proteasomal, mechanism during 
apoptosis, or it may be cleaved by a protease. Whole-membrane blotting with 
SUMI-1 antibody has not detected any low molecular weight cleavage products, 
although if cleavage occurred inside the antibody recognition site, the antibody 
may no longer be able to recognize the resulting SUMI-1 fragments.  
 If SUMI-1 does oligomerize during apoptosis, this phenomenon could be a 
mechanism to regulate SUMI-1’s function. Oxidation-induced oligomerization of 
SUMI-1 may trigger its translocation from the mitochondria, for example.  
Apoptosis often involves generation of free radicals, resulting in oxidation that 
could stimulate disulfide-bond formation and oligomerization. Alternatively, 
oligomerization of SUMI-1 could occur as a result of its translocation, but this is 
unlikely, as disulfide bonds do not typically occur in reducing environments such 
as the nucleus and cytoplasm (although they may remain stable in these 
locations after being formed elsewhere); such oxidation is only known to occur in 
specific compartments of the cell such as the endoplasmic reticulum and 
mitochondria. Thus, oligomerization of SUMI-1 is likely to precede its 
translocation. SUMI-1 oligomerization may also occur as a side effect of 
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apoptosis rather than as a regulatory mechanism for SUMI-1; that is, in the 
absence of oligomerization, SUMI-1 may become inactivated through 
translocation or another means. The regulation of SUMI-1 is an important area 
for future studies.  
 
Materials and Methods 
 
Cell culture, transfections, and apoptotic treatments. U2OS and HeLa cells 
were obtained from ATCC. All cells were cultured in a 37°C incubator with 5% 
CO2 in DMEM supplemented with 10% FBS, 100 U/ml penicillin, and 100 g/ml 
streptomycin. DNA transfections were carried out with Fugene-6 or Fugene-HD 
(Roche), and siRNA transfections were performed with Oligofectamine 
(Invitrogen), according to the manufacturers’ instructions. Apoptosis treatments 
included UVC radiation (dosages as indicated) using a Stratalinker® UV 
Crosslinker, and various reagents and doses as indicated. Where indicated, cells 
were pre-incubated with MG132 for 1 h before apoptotic treatments. 
 
Adenoviruses. Recombinant adenoviruses expressing untagged SUMI-1 or 
GFP were produced using the AdEasy™ XL Adenoviral Vector System 
(Stratagene) according to the manufacturer’s protocol.  
 
SDS-PAGE and western blotting. Cells were lysed in 0.5% NP-40 buffer, and 
lysates were resolved on a 15% polyacrylamide gel and transferred onto a 0.2 
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µM nitrocellulose membrane. Membranes were blocked for a minimum of 30 
minutes in phosphate-buffered saline blocking buffer with 0.1% Tween-20 
(PBST) and 5% nonfat dried milk. Membranes were incubated for 2h to overnight 
in primary antibody, incubated for 1-2 hours in secondary HRP-conjugated 
antibody, and exposed with Supersignal West Pico or Dura (Pierce).  
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Figure 5-1. Apoptotic stimuli reduce the level of endogenous SUMI-1.  
A) U2OS cells were treated with various apoptosis-inducing agents for 18 hours, 
lysed, resolved by SDS-PAGE, and blotted for actin (loading control) and SUMI-
1. UV, 6 mJ/cm
2
. Staurosporine (STS), 10 µM. Doxorubin (DOX), 10 µM. 
Cisplatin (CIS), 10 µg/ml. Vinblastine (VBL), 25 nM. Taxol (TAX), 50 nM.   
B) HeLa cells were treated with UV (6 mJ/cm
2
) for 18 hours, lysed, resolved by 
SDS-PAGE, and blotted for actin (loading control) and SUMI-1.  
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Figure 5-2. Proteasome inhibitor MG132 does not prevent apoptosis-
associated reduction in SUMI-1 level.  
Where indicated, U2OS and HeLa cells were pre-treated with the proteasome 
inhibitor MG132 (20 µM for 1 h), followed by treatment with apoptosis-inducing 
UV radiation (250 J/m
2
 for 4 h). Lysates were resolved by SDS-PAGE and blotted 
for actin (loading control), Mdm2 and p53 (positive controls for suppression of 
proteasomal degradation by MG132), and SUMI-1. Note that in both cell types, 
treatment with MG132 did not prevent decrease in SUMI-1 level but did prevent 
degradation of p53 and Mdm2.  
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Figure 5-3. High molecular weight bands are detected by SUMI-1 antibody 
when cells are treated to undergo apoptosis. 
A) In U2OS cells treated to undergo apoptosis with increasing doses of UV 
radiation, a dose-dependent decrease is observed in the 17 kD band, while a 
corresponding increase is observed for a higher molecular weight band 
(approximately 65-70 kD) that is detected by the SUMI-1 antibody. Cell lysates 
were resolved by SDS-PAGE in the presence of DTT.  
B) In U2OS cells treated to undergo apoptosis (10 mJ/cm
2
 UV), a higher 
molecular weight (HWM) band detected by the SUMI-1 antibody increased in 
size while the 17 kD band decreased. Samples in first two lanes were heated for 
the standard time period (3 minutes) at 95°C in SDS-DTT sample buffer prior to 
resolving by SDS-PAGE. Heating the lysate from lane 2 for 60 minutes led to a 
partial decrease in the HWM band and an increase in the 17 kD band. 
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Figure 5-4.  Transfection of untagged SUMI-1  increases HMW bands 
detected by SUMI-1 antibody. 
U2OS cells were transfected with pShuttle-SUMI-1 plasmid (expressing 
untagged SUMI-1) or empty pShuttle plasmid (negative control). Two replicates 
are shown. Note that the band around 65 kD increases upon transfection with 
SUMI-1. Ponceau S staining is shown to indicate even loading. 
  
 
 
 
 
 
 
CHAPTER VI 
 
 
DISCUSSION 
 
Identification of Novel Apoptosis-Regulating Proteins 
 Apoptotic cell death has been an area of intense investigation in recent 
years, likely owing to its relevance during development as well as for maintaining 
homeostasis in adult organisms, and due to its contribution in the etiology of 
diverse diseases such as developmental and autoimmune disorders, 
neurodegeneration, and cancer. Research identifying the signaling pathways and 
biological mechanisms by which apoptosis occurs, especially those mechanisms 
by which it is regulated, can help us to better understand developmental and 
homeostasis processes as well as diseases that are affected by dysregulation of 
apoptosis. Ultimately, this knowledge may aid in the development of diagnostic 
and therapeutic tools for these diseases.   
 A critical control point in apoptosis is mitochondrial outer membrane 
permeabilization (MOMP), as cells that have crossed this threshold do not 
recover in most cases. Much has been learned about MOMP in recent years, 
especially the roles of BCL-2 family proteins in regulating this process. However, 
several questions remain to be fully elucidated: What are the exact biochemical 
mechanisms governing MOMP? What are the non-BCL-2 proteins that mediate 
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MOMP? Finally, what is the role of mitochondria, including mitochondria-localized 
proteins, in regulating MOMP?  
In this body of work, we initially sought to identify novel interacting proteins 
for the pro-apoptotic protein, p32, which was previously determined in our lab to 
regulate ARF-mediated MOMP and apoptosis through a mechanism that has 
remained unclear (Itahana and Zhang, 2008). In the process, we identified two 
novel potential regulators of apoptosis, SUMI-1 and MAGE-D2. This study 
examined the functions of these two proteins individually, and future studies will 
explore the interactions between these proteins and p32. Here, MAGE-D2 was 
found to be localized to the nucleus, nucleolus, and mitochondria, and the 
preliminary data presented here suggest that MAGE-D2 may regulate cell cycle 
control and apoptosis, although further studies are necessary to establish a 
definitive function for this protein. SUMI-1 was characterized much more 
extensively in this work and was established as a novel, mitochondria-localized 
inhibitor of apoptosis that functions by regulating mitochondrial dynamics, BAX 
activation, and mitochondrial outer membrane permeabilization. Identification of 
these proteins will fill some of the gaps in our knowledge of signaling pathways 
and mechanisms regulating apoptosis—especially MOMP—and may provide a 
potential therapeutic target for diseases that are affected by aberrant regulation 
of apoptosis.  
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MAGE-D2 Localization and Function 
 MAGE-D2 is a ubiquitously expressed, uncharacterized member of the 
MAGE (melanoma antigen) family of proteins, and its increased expression is 
associated with some cancers. The functions of most MAGE proteins in normal 
tissues are unclear, but other proteins belonging to the MAGE-D subfamily have 
been identified to regulate cell cycle progression and apoptosis. In this work, we 
examined the localization and potential functions for this protein. To study 
MAGE-D2, several plasmids were generated to express both N-terminally and C-
terminally tagged MAGE-D2 fusion proteins, and two rabbit polyclonal antibodies 
were produced in order to study endogenous MAGE-D2 by western blotting, 
immunofluorescence, and co-immunoprecipitation.  
 By examining both ectopically-expressed tagged MAGE-D2 and 
endogenous MAGE-D2 by immunofluorescence, the localization of MAGE-D2 
was determined to be primarily nuclear and nucleolar, with a portion of MAGE-D2 
likely residing in or on the mitochondria as well. To determine whether MAGE-D2 
indeed localizes to the mitochondria, a subcellular fractionation and western blot 
could be carried out. Interestingly, the localization of MAGE-D2 was found to be 
heterogeneous among cells, with some cells exhibiting primarily mitochondrial 
staining and other cells displaying mostly nuclear or nucleolar staining.  
 The ability of MAGE-D2 to regulate apoptosis was examined briefly. Cells 
transfected with MAGE-D2-Flag appeared more sensitive to UV-induced 
apoptosis as assessed by examining cell number and morphology and through 
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flow cytometry analysis of DNA content. However, quantification of apoptosis by 
analysis of sub-G1 DNA content is not necessarily an accurate measurement for 
cells that are actively cycling, as it is not possible in this type of cells to 
distinguish apoptotic cells from fragmented cells or other debris. An alternative or 
additional quantitative measure should be used, such as cell counting, and 
specific markers of apoptosis should be examined, such as cleavage of PARP or 
Caspase-3. In addition, overexpression of proteins, especially tagged constructs, 
can yield data artifacts for various reasons: Relative protein levels may be 
critical, and the tagged protein may not behave in the same manner as the 
untagged protein. Stronger evidence of a protein’s function can be provided by 
inhibiting the protein through RNA interference. An experiment examining the 
effect of MAGE-D2 siRNA on apoptosis would help clarify whether MAGE-D2 is a 
bona fide regulator of apoptosis. 
If MAGE-D2 is found to regulate apoptosis, the next step in characterizing 
this protein would be to determine the mechanism by which it regulates 
apoptosis. We found MAGE-D2 to be localized in the nucleus, nucleoli, and 
possibly mitochondria, and this localization does not appear to change during 
apoptosis (data not shown). It is possible that the apoptosis-regulating function of 
MAGE-D2 could be carried out in any of these compartments, especially the 
nucleus and mitochondria, where control of apoptosis is known to take place. In 
the nucleus, MAGE-D2 could regulate protein transcription. As described in 
Chapter III, MAGE-D2’s closest homolog—MAGE-D1/NRAGE—acts as a 
transcription cofactor. MAGE-D1 interacts with several transcription factors that 
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regulate apoptosis and cell cycle control, and is required for Dlx5-dependent 
transcription (Masuda et al., 2001). MAGE-D1’s pro-apoptotic function is also 
shown to be mediated by the transcription factor p53 (Kendall et al., 2005; Wen 
et al., 2004). MAGE-D2 has also been reported to interact with p53 (Papageorgio 
et al., 2007), which becomes activated following extensive DNA damage or other 
apoptotic signals, leading to transcription of apoptosis-inducing genes such as 
NOXA and PUMA. RT-PCR studies with and without MAGE-D2 knockdown and 
overexpression could be used to determine whether MAGE-D2 affects the ability 
of p53 to induce these target genes during apoptosis. MAGE-D2 might act as a 
transcriptional cofactor for p53; that is, if MAGE-D2 promotes apoptosis, it might 
enhance the ability of p53 to induce transcription of NOXA, PUMA, or other 
apoptosis-regulating genes during apoptosis. In this case, one would expect to 
see increased mRNA transcripts of these genes by RT-PCR when MAGE-D2 is 
overexpressed, and/or decreased transcription when MAGE-D2 is inhibited with 
RNAi. Western blotting should also be carried out under these experimental 
conditions to determine whether the corresponding protein levels are also 
increased by expression of MAGE-D2. To determine whether any transcription-
regulating effect of MAGE-D2 is indeed mediated by p53, these experiments 
could be performed in both WT and p53-null mouse embryo fibroblasts (MEFs); if 
MAGE-D2 functions by modulating the activity of p53, it would not be expected to 
affect gene transcription in p53-null cells. It would also be interesting to 
determine whether MAGE-D2 affects p53-mediated transcription globally or just 
for apoptosis-regulating genes. It is also possible that, even though an interaction 
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was reported between p53 and MAGE-D2, MAGE-D2 may mediate transcription 
independently of p53, or that MAGE-D2 may interact with mitochondria-localized 
p53 during apoptosis to affect p53’s non-transcription-related functions (such as 
its interaction with BCL-2 family proteins) at the mitochondria. Alternatively, a 
luciferase assay using a p53-responsive promoter could be used to examine the 
effect of MAGE-D2 on p53’s transcriptional activity, but the RT-PCR approach 
has the advantage of assessing multiple p53 targets at once and, importantly, it 
assesses transcription of endogenous DNA promoters (complete with any 
associated proteins) and is therefore more likely to accurately recapitulate 
transcriptional regulation in vivo.  
 The putative interaction between MAGE-D2 and p53 is not well-
established, and it is possible that MAGE-D2 regulates apoptosis independently 
of p53. We found that MAGE-D2 binds with the pro-apoptotic protein p32 and the 
anti-apoptotic protein SUMI-1, and it is likely that MAGE-D2 modulates apoptosis 
through its interaction with one or both of these proteins. Potential experiments 
exploring this possibility will be discussed later in this chapter. Finally, MAGE-D2 
could influence apoptosis independently of presently-known interacting proteins. 
In this case, it might regulate apoptosis through interaction with another binding 
partner, and a large-scale co-immunoprecipitation to look for novel interacting 
partners could provide clues for its function. As there is thought to be extensive 
redundancy among MAGE proteins, it is also reasonable to examine the 
mechanisms by which other MAGE family members, especially those in the 
MAGE-D subfamily, regulate apoptosis. As mentioned above, MAGE-D1-
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mediated apoptosis is known to require the transcription factor p53, implicating 
transcriptional regulation as a potential mechanism for MAGE-D2’s function. 
However, MAGE-D1 can also activate c-Jun N-terminal kinase (JNK), leading to 
MOMP and apoptosis (Salehi et al., 2002), and MAGE-D1 interacts transiently 
with XIAP and may lead to degradation of this anti-apoptotic protein during 
apoptosis (Jordan et al., 2001). It is possible that MAGE-D2, which shares 
extensive sequence homology with MAGE-D1, may regulate apoptosis through 
one of these mechanisms.  
 MAGE-D2 may also regulate cell cycle progression. In patches of 
confluent U2OS cells, MAGE-D2 expression was decreased significantly. This 
suggests that MAGE-D2 might either regulate, or be regulated by, the cell cycle. 
Additionally, in a flow cytometry experiment, it was observed that cells 
transfected with MAGE-D2-Flag yielded a higher peak representing the G1 
phase of the cell cycle compared to mock-transfected cells, as determined 
visually, although the percentages of cells in each phase have not been 
quantified. It would be interesting to carry out additional experiments to 
determine whether MAGE-D2 affects cell cycle progression. First, the above-
mentioned flow cytometry experiment could be repeated and quantified. siRNA 
could be used to determine whether MAGE-D2 knockdown causes the opposite 
effect. That is, can inhibition of MAGE-D2 decrease the proportion of G1 phase 
cells? 
 To determine whether MAGE-D2-Flag expression induces cell cycle 
arrest, cellular proliferation could be monitored to determine whether cell division 
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slows in MAGE-D2-Flag expressing cells compared to untreated cells. 
Additionally, a BRDU-incorporation assay could be used to assess whether 
MAGE-D2-Flag-transfected cells arrest at G1 or progress into S (DNA synthesis) 
phase. When BRDU (bromodeoxyuridine) is added to cycling cells, it becomes 
incorporated into the new DNA that is produced during S phase. A decrease of 
BRDU incorporation indicates that fewer cells are entering S phase, and cell 
cycle arrest may be occurring. MAGE-D2 expression is heterogeneous from cell 
to cell in terms of both quantity and localization. That is, cells express varying 
amounts of MAGE-D2, with localization appearing primarily nuclear/nucleolar in 
some cells and primarily mitochondrial in other cells. These differences may 
correspond to cell cycle progression. To determine whether the cell cycle stage 
affects MAGE-D2 expression and/or localization, cells could be treated with 
cycloheximide to synchronize the cell cycle and then fixed at various time points 
to be examined by immunofluorescence (to assess localization) and western 
blotting (to assess protein level). To determine whether MAGE-D2 expression 
correlates with a specific cell cycle phase, markers of the various cell cycle 
phases could be examined simultaneously. These results would yield clues to the 
mechanism by which MAGE-D2 might regulate, or be regulated by, the cell cycle. 
The absence of MAGE-D2 in some confluent cells seems contradictory to the 
data showing that overexpression of MAGE-D2-FLAG might increase the 
percentage of cells in G1. Again, the tag could be affecting the function of the 
protein, or overexpression might cause non-physiological results. The 
experiments described above can help to determine whether MAGE-D2 plays a 
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role in cell cycle control, and whether it promotes or inhibits cell cycle 
progression.  
 The preliminary data presented here suggest that MAGE-D2 may have a 
pro-apoptotic function and/or a cell-cycle-inhibitory function. However, it must be 
considered that these experiments were based on ectopic protein 
overexpression, which can yield artifacts and should be complemented by 
knockdown data when possible. Ratios among proteins can be critical for normal 
functioning, and gross overexpression can cause other functions not observed 
with the endogenous protein, such as aberrant localization or sequestering of 
another protein. Therefore, knockdown data using RNAi is generally considered 
more reliable and would greatly aid in determining the true, in vivo, functions of 
MAGE-D2. Tags can also interfere with protein function, and MAGE-D2-Flag may 
not behave the same as untagged MAGE-D2 in cells. Data from MAGE-D2-Flag 
overexpression suggest a potential pro-apoptotic or proliferation-inhibitory 
function. However, expression of MAGE-D2 is elevated in a number of cancers, 
and this would be more consistent with the opposite role for MAGE-D2 (anti-
apoptosis and/or pro-proliferation). It is possible that the Flag tag interferes with 
the function of MAGE-D2. This issue could be resolved by transfecting cells with 
untagged MAGE-D2 and/or MAGE-D2 tagged at the other terminus. 
 Our studies have not addressed how MAGE-D2 itself is regulated during 
apoptosis and/or cell cycle control, or what upstream signaling pathways may 
lead to its activation. A large-scale screen for substrates of ATM/ATR found that 
MAGE-D2 is phosphorylated by these proteins at several serine residues 
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following DNA damage (Matsuoka et al., 2007). ATM (ataxia telangiectasia, 
mutated) and ATR (ATM and Rad3-related) are serine-threonine protein kinases 
that act as key regulators of the DNA damage cell cycle checkpoint. ATM 
responds to DNA double-strand breaks, while ATR primarily mediates response 
to UV radiation and stalled DNA replication. Activation of these proteins leads to 
G1 cell cycle arrest mediated by p53, allowing time for cells to repair DNA 
damage prior to dividing (Matsuoka et al., 2000; Maya et al., 2001; Shieh et al., 
2000). In the event of extensive (irreparable) DNA damage, activation of 
ATM/ATR, in conjunction with activation of other signaling pathways, can induce 
apoptosis (Norbury and Zhivotovsky, 2004). To determine whether MAGE-D2 
mediates ATM/ATR-induced response to DNA damage by regulating cell cycle 
arrest and/or apoptosis, the ability of ATM/ATR to regulate these events could be 
assessed with and without MAGE-D2 knockdown. The four serines in MAGE-D2 
that are reported to be phosphorylated by ATM/ATR could be mutated to 
determine whether the effects of these proteins depend specifically on 
phosphorylation of MAGE-D2 at these residues.  
 Overall, the data presented here suggest an interesting potential role for 
MAGE-D2 in mediating apoptosis and/or a cell cycle checkpoint, and 
examination of various aspects of MAGE-D2—reported functions of homologs as 
well as interacting proteins and modifications of MAGE-D2—provides several 
compelling directions for future research. This work provides a foundation from 
which to study the functions and mechanisms of MAGE-D2 and provides 
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valuable tools (expression plasmids and two effective and specific antibodies) 
with which to carry out these studies. 
 
Regulation of Apoptosis by SUMI-1 
 In this work, SUMI-1 is characterized as a novel regulator of BAX-
mediated apoptosis. We show that in healthy cells, SUMI-1 resides at the 
mitochondria, where it regulates mitochondrial dynamics. We present a model in 
which SUMI-1’s exodus from mitochondria during apoptosis inhibits mitochondrial 
fusion, while fission proceeds as normal, resulting in fragmented yet intact 
mitochondria. This fragmentation promotes oligomerization of BAX, leading to 
mitochondrial outer membrane permeabilization (MOMP), cytochrome c release, 
Caspase activation, and apoptosis.  Data from Oncomine show that SUMI-1 is 
upregulated in a variety of cancers, consistent with its anti-apoptotic function. 
Likewise, we show that SUMI-1 is overexpressed in cancerous human cell lines 
compared to non-transformed cells and that inhibition of SUMI-1 sensitizes cells 
to chemotherapeutic-induced apoptosis. Together, these data suggest that 
SUMI-1 may represent a potential chemosensitizing therapeutic target for cancer 
treatment.  
 While we show that SUMI-1 regulates mitochondrial dynamics and 
oligomerization of BAX, the exact biochemical mechanisms of SUMI-1’s function 
remain unknown. Mitochondrial fusion is mediated by Mitofusins 1 and 2 (MFN1 
and MFN2), and these Mitofusins on adjacent mitochondria homo-or hetero-
dimerize to anchor mitochondria together and induce fusion. SUMI-1 may interact 
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with one or both Mitofusins in order to promote their function, or it may affect 
fusion indirectly through another mechanism. BAK, in addition to oligomerizing to 
induce MOMP during apoptosis, also interacts with Mitofusins and regulates 
mitochondrial dynamics during apoptosis. During apoptosis, binding between 
BAK and MFN1 increase, and this interaction inhibits fusion, leading to 
mitochondrial fragmentation and promoting MOMP (Brooks et al., 2007). 
Preliminary data show that inhibition of SUMI-1 with RNAi increases the level of 
BAK protein. Apoptosis induced by UV also increases the level of BAK, and 
SUMI-1 knockdown augments the UV-mediated BAK increase (data not shown). 
It is possible that SUMI-1 normally keeps the level of BAK in check, maintaining 
the ability of mitochondria to fuse. During apoptosis, inhibition of SUMI-1 (such 
as by translocation from the mitochondria, a decrease in level, and/or 
oligomerization), may lead to increased BAK levels, thereby inhibiting fusion and 
sensitizing cells to BAX- and/or BAK-mediated MOMP and apoptosis. Further 
studies could be carried out to determine whether SUMI-1 indeed regulates BAK, 
and through what mechanism (e.g. protein degradation or inhibition of 
transcription) and whether SUMI-1 modulates mitochondrial dynamics and 
apoptosis through BAK or an alternative mechanism.  
It is not known how SUMI-1 itself is regulated during apoptosis. We have 
shown that SUMI-1 translocates from the mitochondria during apoptosis prior to 
cytochrome c in order to regulate MOMP. However, the stimulus triggering this 
translocation is unknown. Preliminary data described in Chapter V suggest that 
SUMI-1 might oligomerize during apoptosis. This oligomerization, mediated by 
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disulfide bond interactions between cysteines in the CHCH domain, would almost 
certainly be regulated by RedOx status. Generally, an increase in oxidation 
induces formation of disulfide bonds, although variations in oxidation might 
influence whether these bonds form intramolecularly (generating a hairpin or loop 
in the CHCH domain) or between SUMI-1 molecules to create an oligomer—It is 
not yet known whether a monomer with intramolecular disulfide bonds or a 
disulfide-bond-mediated oligomer represents the fully-oxidized state of SUMI-1. 
This could be explored by altering the RedOx status of cells and examining the 
effect on development of higher molecular weight SUMI-1 bands by western 
blotting. Given that free radical production is associated with apoptosis, and that 
SUMI-1 appears to oligomerize during apoptosis, it is likely that SUMI-1 
oligomers represent a more oxidized state than the monomers. One hypothesis 
for regulation of SUMI-1 during apoptosis is that SUMI-1 responds to changes in 
RedOx status by forming disulfide-bond-mediated oligomers, inducing its 
translocation from the mitochondria. Presumably, this RedOx stimulus would be 
oxidation induced by free radical generation. This idea could be tested by 
performing a subcellular fractionation to determine the localization of SUMI-1 
monomers and putative oligomers during apoptosis. Mutations could be 
generated in cysteines of the CHCH domain (i.e. cysteine-to-alanine mutations) 
in order to determine whether translocation of SUMI-1 during apoptosis relies on 
disulfide bond formation involving two or more of the four cysteines in this 
domain.  
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Alternatively, SUMI-1 may be regulated by another mechanism such as 
phosphorylation. Another CHCH-domain-containing protein, CHCHD3, was 
recently identified as a substrate for cAMP-dependent protein kinase A (PKA) 
(Schauble et al., 2007). CHCHD3 was characterized earlier this year as an inner 
mitochondrial membrane protein that maintains mitochondrial function and crista 
integrity (Darshi et al., 2011). Upon phosphorylation of CHCHD3 by PKA at 
Threonine 10 (Thr10), CHCHD3 translocates from the mitochondria to the 
nucleus, although the function for this PKA-induced translocation is unknown. 
According to analysis by KinasePhos (Huang et al., 2005), SUMI-1 also contains 
a predicted PKA phosphorylation site, located at Thr9.  Perhaps phosphorylation 
by PKA at this site might induce translocation of SUMI-1 during apoptosis. PKA 
can be activated by cyclic AMP (cAMP) to induce mitochondrial outer membrane 
permeabilization and apoptosis through mechanisms that are not well understood 
(Zhang et al., 2008). If SUMI-1 is phosphorylated by PKA, leading to its 
translocation during apoptosis, this would provide a link between PKA activation 
and sensitivity to mitochondrial outer membrane permeabilization during 
apoptosis. To determine whether SUMI-1 is a substrate of PKA, an in vitro kinase 
assay could be performed using combinations of SUMI-1, PKA, and radiolabeled 
ATP. Additional experiments could be carried out in intact cells by adding an 
inducer of cAMP with and without PKA knockdown and assessing the effect on 
SUMI-1 phosphorylation.  
To assess whether Thr9 is indeed the phosphorylation site, a threonine-to-
alanine mutation could be generated at residue 9 (T9A) to prevent 
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phosphorylation. As negative controls, other threonines and serines could be 
mutated to alanine to generate mutants that can still potentially be 
phosphorylated at Thr9. If the phosphorylation site is identified, phospho-specific 
antibodies could be developed to more easily detect the phosphorylation status 
of SUMI-1. 
To find out whether the translocation of SUMI-1 depends on 
phosphorylation at Thr9, a T9A mutation could be generated to prevent 
phosphorylation. If Thr9 is required for mitochondrial translocation of SUMI-1, 
apoptotic stimuli should fail to induce translocation of the T9A mutant. Mutation of 
threonine to glutamic acid can mimic phosphorylation (Wheatley et al., 2004); a 
T9E mutation could, therefore, induce SUMI-1 translocation. Together, these 
data would provide strong evidence that phosphorylation of SUMI-1 at Thr9 is the 
trigger for SUMI-1’s exodus from the mitochondria.  
Experiments to determine how SUMI-1 translocates during apoptosis will 
provide insight into mechanisms by which SUMI-1’s function can be manipulated. 
This knowledge could aid in the development of chemosensitizing drugs to inhibit 
SUMI-1, assuming that subsequent studies show that SUMI-1 is a suitable target 
for inhibition in cancer treatment. 
A significant strength of the studies presented here is that they were 
carried out in intact cells, primarily using endogenous proteins. In the few cases 
in which ectopic expression was utilized, cells were usually transfected with non-
tagged SUMI-1. The importance of these points was highlighted by a recent 
study reporting SUMI-1 as a modulator of cell migration (Seo et al., 2010). In that 
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paper, SUMI-1 was identified in a screen for novel cell-migration-regulating 
proteins, and several experiments were carried out to confirm this function. 
SUMI-1 was reported in that study to localize to the cytosol rather than the 
mitochondria, but the authors had assessed localization only by ectopic 
expression of an N-terminally-tagged SUMI-1 construct. As shown in Figure 4-6E 
of this work, an N-terminal tag blocks the mitochondrial localization of SUMI-1. 
Thus, the reported localization of SUMI-1 in the study by Seo et al. does not 
represent that of the endogenous protein. Furthermore, the authors claimed that 
co-transfection of p32 with SUMI-1 inhibited SUMI-1’s function. However, the 
authors had transfected cells with an N-terminally tagged p32 whose 
mitochondrial targeting was also disrupted, causing the tagged p32 to localize to 
the cytosol rather than mitochondria. This means that both transfected proteins 
were incorrectly localized and grossly overexpressed, which affects how the data 
can be interpreted. When localized to a different cellular compartment, the 
interaction between the proteins may be altered, and overexpression of 
cytoplasmic p32 might have sequestered the cytoplasmic SUMI-1 or affected 
SUMI-1 in some manner that does not occur when both proteins are in the 
mitochondria. For example, the nature of the interaction between p32 and SUMI-
1 might be different when SUMI-1 is embedded in the mitochondrial outer 
membrane as opposed to in its soluble form, and the disulfide bond formation—
and therefore the intra- and inter-molecular structure—will differ between the 
oxidative environment of the mitochondria and the reducing environment of the 
cytosol. 
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While the studies here were carried out in intact cells and relying mostly 
on endogenous proteins—conferring many benefits over in vitro and ectopic 
expression experiments—studies using immortalized cell lines do not always 
recapitulate what occurs in a live organism. To address this issue, SUMI-1 
knockout mice could be generated for in vivo studies. Because SUMI-1 
knockdown will probably increase apoptosis in the mouse as it does in human 
cell culture, it is likely that development will be disturbed by this deletion or that 
embryonic lethality may result. Further complicating the issue is that SUMI-1 has 
also been identified in screens for regulators of oxidative phosphorylation and 
cell migration, and both of these processes are essential during development. In 
the case of embryonic lethality, a conditional knockout mouse could be 
generated using a Cre/LoxP system to ablate SUMI-1 in specific mouse tissues. 
From these mouse knockout studies, we could determine whether SUMI-1 
functions similarly in a live organism as in cell culture. The effect of SUMI-1 
knockdown on apoptosis in vivo can be assessed using TUNEL staining of fixed 
mouse tissues, or of fixed embryo tissue in the case of embryonic lethality. 
Mouse embryo fibroblast (MEF) cells generated from these mice can also be 
used for experiments to assess the role of SUMI-1 in non-cancerous cells. An 
advantage here is that SUMI-1 expression can be completely ablated. It is 
difficult to transfect non-cancerous cell lines such as WI38 and BJ cells with 
siRNA, but SUMI-1-null MEFs should have complete abrogation of SUMI-1 
expression and would provide another means by which to study non-transformed 
cells. These cells could also help answer questions about SUMI-1 
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oligomerization, as the HMW bands detected by western blotting with SUMI-1 
antibody should be completely eliminated in SUMI-1-null MEFs, whereas with 
siRNA only partial knockdown is achieved, and if the oligomer form of SUMI-1 is 
favored, it may not disappear with siRNA treatment. 
Several data suggest that SUMI-1 may be a candidate drug target for 
chemosensitizing agents in cancer treatment: SUMI-1 is an anti-apoptotic 
protein, and evasion from apoptosis is a hallmark of cancer; elevated SUMI-1 
expression correlates with transformation of cell lines; SUMI-1 is elevated in a 
wide variety of human cancers; and inhibition of SUMI-1 sensitizes cancer cell 
lines to apoptosis induced by chemotherapeutic agents such as doxorubicin and 
cisplatin. Before SUMI-1 can be considered a valid drug target, additional studies 
are needed. First it should be determined whether SUMI-1 knockdown promotes 
shrinkage of tumors in nude or SCID (immune-compromised) mice; based on cell 
culture data, it is likely that SUMI-1 inhibition will sensitize the ectopic tumors to 
treatment with chemotherapeutic drugs. It is difficult to utilize siRNA in this type 
of experiment as the siRNA becomes quite dilute during the initial proliferation of 
tumor cells. To avoid this issue, a dominant-negative SUMI-1 (SUMI-1 c-
terminally tagged with Flag) could be used to inhibit SUMI-1; tumor cells stably-
expressing SUMI-1-Flag could be compared with mock-transfected cells. 
In summary, the data presented here establish SUMI-1 as a novel 
regulator of mitochondrial fusion/fission dynamics and BAX-mediated apoptosis, 
and because the experiments were performed in live cells using mostly 
endogenous proteins, they are likely to be physiologically relevant. Future studies 
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can help us to learn the upstream signaling pathways that regulate SUMI-1, to 
understand whether SUMI-1 functions the same way in a live organism as it does 
in cell culture, and to determine whether SUMI-1 is a suitable target for cancer 
therapeutics.  
 
Roles for Interactions Among p32, SUMI-1, and MAGE-D2 
 In this study, SUMI-1 and MAGE-D2 were both identified as binding 
partners for p32, and MAGE-D2 and SUMI-1 were also found to interact with 
each other. The initial rationale behind the search for p32-interacting proteins 
was to better understand the function of p32; we hoped to find an interaction with 
a known apoptosis-regulating protein that would provide clues regarding the 
mechanisms by which p32 regulates apoptosis. No such proteins were found 
among the eleven putative p32-interacting partners identified, but SUMI-1 and 
MAGE-D2 appeared to be promising candidates for novel regulators of 
apoptosis, and we elected to first characterize the functions of these two proteins 
on their own, independent of their interactions with p32. To understand the 
mechanisms of these three proteins in more detail, it would be helpful to 
determine the purpose for their interactions with one another.   
Several studies could be carried out to determine the nature of the 
relationship between SUMI-1 and p32. First, it should be determined whether p32 
interacts with SUMI-1 and/or MAGE-D2 to regulate apoptosis, and which protein 
is upstream and which is downstream in this pathway—that is, does p32 regulate 
SUMI-1 and MAGE-D2, or vice versa? To accomplish this, various 
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overexpression and knockdown experiments can be utilized. For example, SUMI-
1 could be overexpressed with and without p32 knockdown or overexpression, 
and the ability of SUMI-1 overexpression to inhibit apoptosis could be assessed. 
If p32 acts downstream of SUMI-1, then its inhibition or overexpression might 
affect the ability of SUMI-1 overexpression to block apoptosis. By performing 
various combinations of these experiments, it can be determined whether the 
p32-SUMI-1 or p32-MAGE-D2 interactions mediate apoptosis, as well as whether 
p32 lies upstream or downstream of these proteins in the respective pathways. It 
is also possible, however, that p32 interacts with one or both proteins in a 
cooperative manner; two of the proteins, or all three, could comprise a complex 
that regulates apoptosis together—in this case, we might find that none of the 
proteins modifies the function of another. It is also possible that SUMI-1 and p32 
do not interact to regulate apoptosis. Both proteins have reported roles in 
oxidative phosphorylation, and it is possible that they interact to mediate cellular 
metabolism, apoptosis, or both processes.   
After a purpose for the interaction is established, the mechanism for this 
regulation can be explored. Mapping experiments indicate which specific 
domains interact and can often provide leads regarding how one protein might 
regulate another. Mapping can be accomplished by generating tagged deletion 
mutants of each protein and carrying out a co-immunoprecipitation to identify 
which peptides interact. Deletion mutants for p32 are available from a previous 
lab member, and I have designed and produced six Myc-tagged deletion mutants 
each for SUMI-1 and MAGE-D2 (Figure 6-1). In addition to mapping, it can be 
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determined whether inhibition or overexpression of one protein affects the other’s 
expression level or localization. Knockdown of SUMI-1 does not appear to affect 
the level of endogenous p32 detected by western blotting with a p32 antibody 
(data not shown). However, another antibody that is marketed as a BCL-xL 
antibody (Santa Cruz, anti-BCL-x S-18, sc634) recognizes two strong bands (on 
a western blot) of approximately 34 and 37 kD in size that, surprisingly, represent 
p32 rather than BCL-xL (Figure 4-20). During apoptosis, these bands shift—the 
34 kD band disappears, while the 37 kD band becomes stronger (Figure 4-19). 
This shift in migration of p32 may represent a modification of p32 that occurs 
during apoptosis. Interestingly, knockdown of SUMI-1 promotes this shift in 
migration and even induces a partial shift in the absence of apoptotic stimuli, 
suggesting that SUMI-1 inhibits this modification of p32. During apoptosis, p32 is 
released from the mitochondria concurrent with cytochrome c (unpublished data 
from our laboratory), while SUMI-1 translocates prior to cytochrome c, suggesting 
that SUMI-1 translocates before p32 and therefore dissociates from p32 upon its 
exit from the mitochondria.  Translocation of SUMI-1 from the mitochondria 
(causing its release from p32), might promote p32 modification, allowing MOMP 
and apoptosis to proceed.    
Upon examination of the BCL-xL S-18 antibody and attempts to determine 
how it recognizes p32, it was found that p32 contains an area of homology with 
BCL-xL within the N-terminal BH4 domain (Figure 4-21). Apparently, this region 
of p32 mimics the BH4 domain of BCL-xL well enough to induce strong binding 
between the BCL-xL antibody and p32. This suggests that p32 might contain a 
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BH4-mimetic domain. Perhaps p32 can interact with or mimic other BCL-2 family 
members via this domain. A previous lab member performed a co-
immunoprecipitation experiment searching for interactions between p32 and 
several BCL-2 family members, with inconclusive results (data not shown). It is 
possible that p32 interacts with one of these proteins transiently, or more likely, 
that p32 interacts with these proteins only during apoptosis; for example, the 
potential BH4-mimetic domain could be hidden by SUMI-1 until SUMI-1 
translocates from the mitochondria during apoptosis.  It would be interesting to 
explore this hypothesis with additional co-immunoprecipitation experiments in the 
presence of apoptotic stimuli, using crosslinking to preserve weak or transient 
interactions if necessary.  
Data published by Itahana and Zhang show that p32 regulates apoptosis 
by recruiting ARF to the mitochondria, inducing a change in mitochondrial 
membrane potential and sensitizing cells to apoptotic stimuli (Itahana and Zhang, 
2008). It is possible that ARF dissociates SUMI-1 from p32, causing SUMI-1 
translocation from mitochondria. Alternatively, SUMI-1 might sequester p32, 
preventing its interaction with ARF until SUMI-1 translocates during apoptosis. It 
is unknown whether these three proteins can exist in a complex together, or 
whether SUMI-1 can influence the ability of p32 and ARF to interact together. A 
sequential co-IP could determine whether the proteins are part of the same 
complex. To determine whether SUMI-1 affects the p32-ARF interaction, a co-IP 
between p32 and ARF could be carried out with and without siRNA knockdown of 
SUMI-1.   
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Establishing a purpose and mechanism for the interactions among p32, 
MAGE-D2, and SUMI-1 will provide mechanistic insights into the functions of 
these proteins and may identify a novel signaling pathway in regulating 
apoptosis.  
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Figure 6-1. MAGE-D2 deletion mutants. 
Six Myc-tagged MAGE-D2 deletion mutants have been generated for mapping 
the interaction between MAGE-D2 and p32 or other proteins.  
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Figure 6-2. SUMI-1 deletion mutants. 
Six Myc-tagged SUMI-1 deletion mutants have been generated for mapping the 
interaction between SUMI-1 and p32 or other proteins.  
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